

FORM PTO-1390  
(REV 5-93)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTORNEY'S DOCKET NUMBER

**TRANSMITTAL LETTER TO THE UNITED STATES  
DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING  
A FILING UNDER 35 U.S.C. 371**

2055MC/48896

U.S. APPLICATION NO. (if known, see 37 CFR 1.5)

**09/554414**INTERNATIONAL APPLICATION NO.  
PCT/CA98/01059INTERNATIONAL FILING DATE  
12 November 1998PRIORITY DATE CLAIMED  
12 November 1997TITLE OF INVENTION  
DNA DEMETHYLASE, THERAPEUTIC AND DIAGNOSTIC USES THEREOFAPPLICANT(S) FOR DO/EO/US  
Moshe SZYF; Sanjoy BHATTACHARYA; Shyam RAMCHANDANI


Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371
3. ☒ This express request to begin national examination procedures (35 U.S.C. 371(f) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).
4. ☒ A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
5. ☒ A copy of the International Application as filed (35 U.S.C. 371(c)(2)).
  - a. ☐ is transmitted herewith (required only if not transmitted by the International Bureau).
  - b. ☒ has been transmitted by the International Bureau
  - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US)
6. ☒ A translation of the International Application into English (35 U.S.C. 371(c)(2)).
7. ☐ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))
  - a. ☐ are transmitted herewith (required only if not transmitted by the International Bureau).
  - b. ☐ have been transmitted by the International Bureau.
  - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
  - d. ☐ have not been made and will not be made.
8. ☐ A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9. ☒ An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). **UNEXECUTED**
10. ☐ A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

**Item 11. to 16. below concern other document(s) or information included:**

11. ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
12. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. ☒ A **FIRST** preliminary amendment.  
☐ A **SECOND** or **SUBSEQUENT** preliminary amendment.
14. ☐ A substitute specification.
15. ☐ A change of power of attorney and/or address letter.
16. ☒ Other items or information:  
Form PCT/IB/308  
Copy of International Preliminary Examination Report  
Computer Readable Form of Sequence Listing  
Statement under 37 CFR 1.821 (f)  
Executed Small Entity Status Declaration

U.S. APPLICATION NO (if known, see 37 CFR 1.5)		INTERNATIONAL APPLICATION NO		ATTORNEY'S DOCKET NUMBER	
09/554414		PCT/CA98/01059		2055MC/48896	
17. <input checked="" type="checkbox"/> The following fees are submitted: Basic National Fee (37 CFR 1.492(a)(1)-(5)):				CALCULATIONS	
Search Report has been prepared by the EPO or JPO ..... \$840.00 International preliminary examination fee paid to USPTO (37 CFR 1.482) ... \$670.00 No international preliminary examination fee paid to USPTO (37 CFR 1.482)  but international search fee paid to USPTO (37 CFR 1.445(a)(2)) ..... \$760.00 Neither international preliminary examination fee (37 CFR 1.482) nor  international search fee (37 CFR 1.445(a)(2)) paid to USPTO ..... \$ 970.00 International preliminary examination fee paid to USPTO (37 CFR 1.482)  and all claims satisfied provisions of PCT Article 33(2)-(4) ..... \$96.00				PTO USE ONLY	
ENTER APPROPRIATE BASIC FEE AMOUNT =				\$ 840.00	
Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input checked="" type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(e)).				\$ 130.00	
Claims	Number Filed	Number Extra	Rate		
Total Claims	31 -20=	11	X \$18.00	\$ 198.00	
Independent Claims	4 - 3=	1	X \$78.00	\$ 78.00	
Multiple dependent claims(s) (if applicable)			+ \$260.00	\$	
TOTAL OF ABOVE CALCULATIONS =				\$1,246.00	
Reduction by 1/2 for filing by small entity, if applicable. Verified Small Entity statement must also be filed. (Note 37 CFR 1.9, 1.27, 1.28).				\$	
SUBTOTAL =				\$ 623.00	
Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).				+	
TOTAL NATIONAL FEE =				\$ 623.00	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28,3.31). \$40.00 per property +				\$	
TOTAL FEE ENCLOSED =				\$ 623.00	
				Amount to be: \$	
				refunded	
				charged \$	
a. <input checked="" type="checkbox"/> A check in the amount of \$ <u>623.00</u> for the filing fee is enclosed b. <input type="checkbox"/> Please charge my Deposit Account No. _____ in the amount of \$ _____ to cover the above fees. A duplicate copy of this sheet is enclosed. c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees, which may be required, or credit any overpayment to Deposit Account No. <u>05-1323</u> . A duplicate copy of this sheet is enclosed.					
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.					
SEND ALL CORRESPONDENCE TO: Evenson, McKeown, Edwards & Lenahan, P.L.L.C. 1200 G Street, N.W., Suite 700 Washington, D.C. 20005 Tel. No. (202) 628-8800 Fax No. (202) 628-8844					
				SIGNATURE J. D. Evans NAME 26,269 REGISTRATION NUMBER May 12, 2000	

U.S. APPLICATION NO. <i>if known, see 37 CFR 1.5</i> <b>09/554414</b>		INTERNATIONAL APPLICATION NO PCT/CA98/01059	ATTORNEY'S DOCKET NUMBER 2055MC/48896
17. <input checked="" type="checkbox"/> The following fees are submitted: Basic National Fee (37 CFR 1.492(a)(1)-(5)):  Search Report has been prepared by the EPO or JPO ..... \$840.00 International preliminary examination fee paid to USPTO (37 CFR 1.482) ... \$670.00 No international preliminary examination fee paid to USPTO (37 CFR 1.482)  but international search fee paid to USPTO (37 CFR 1.445(a)(2)) ..... \$760.00 Neither international preliminary examination fee (37 CFR 1.482) nor  international search fee (37 CFR 1.445(a)(2)) paid to USPTO ..... \$ 970.00 International preliminary examination fee paid to USPTO (37 CFR 1.482)  and all claims satisfied provisions of PCT Article 33(2)-(4) ..... \$96.00 <b>ENTER APPROPRIATE BASIC FEE AMOUNT = \$ 840.00</b>			<b>CALCULATIONS</b>          <b>PTO USE ONLY</b>
Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input checked="" type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(e)).			\$ 130.00
Claims	Number Filed	Number Extra	Rate
Total Claims	31 -20=	11	X \$18.00
Independent Claims	4 - 3=	1	X \$78.00
Multiple dependent claims(s) (if applicable)			+ \$260.00
<b>TOTAL OF ABOVE CALCULATIONS =</b>			<b>\$1,246.00</b>
Reduction by 1/2 for filing by small entity, if applicable. Verified Small Entity statement must also be filed. (Note 37 CFR 1.9, 1.27, 1.28).			\$
<b>SUBTOTAL =</b>			<b>\$ 623.00</b>
Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).			\$
<b>TOTAL NATIONAL FEE =</b>			<b>\$ 623.00</b>
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28,3.31). \$40.00 per property +			\$
<b>TOTAL FEE ENCLOSED =</b>			<b>\$ 623.00</b>
			Amount to be: \$
			refunded
			charged \$
a. <input checked="" type="checkbox"/> A check in the amount of \$ <u>623.00</u> for the filing fee is enclosed b. <input type="checkbox"/> Please charge my Deposit Account No. _____ in the amount of \$ _____ to cover the above fees. A duplicate copy of this sheet is enclosed. c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees, which may be required, or credit any overpayment to Deposit Account No. <u>05-1323</u> . A duplicate copy of this sheet is enclosed.			
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.			
SEND ALL CORRESPONDENCE TO: Evenson, McKeown, Edwards & Lenahan, P.L.L.C. 1200 G Street, N.W., Suite 700 Washington, D.C. 20005 Tel. No. (202) 628-8800 Fax No. (202) 628-8844			
			SIGNATURE  J. D. Evans
			NAME 26,269
			REGISTRATION NUMBER May 12, 2000

09/554414  
426 Rec'd PCT/PTO 12 MAY 2000

Attorney Docket: 2055MC/48896  
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: MOSHE SZYF ET AL.

Serial No.: UNASSIGNED

Group Art Unit: UNASSIGNED

Filed: MAY 12, 2000

Examiner: UNASSIGNED

Corresponding to PCT/CA98/01059

November 12, 1998

Title: DNA DEMETHYLASE, THERAPEUTIC AND  
DIAGNOSTIC USES THEREOF

PRELIMINARY AMENDMENT

Box PCT

Commissioner for Patents  
Washington, D.C. 20231

Sir:

Please enter the following amendments to the claims, prior to the examination of the application during the U.S. National Phase.

IN THE CLAIMS:

Claim 4, line 2, change "claims" to --claim-- and delete "or 3".

Claim 10, line 2, change "claims" to --claim-- and delete "or 3".

Claim 11, line 2, change "claims" to --claim-- and delete "or 3".

Claim 15, line 1, delete "or 3".

Claim 16, line 1, delete "or 3".

Claim 19, line 2, delete "or 2".

Claim 23, line 1, change "one of claims" to --claim-- and delete "or 22".

Claim 27, line 1, delete "or its cDNA of";  
line 2, delete "claim 2".

Claim 28, line 1, delete "or its cDNA";  
line 2, delete "of claim 2".

Please add the following new claims:

-- 30. Use of the cDNA of claim 2, for changing the state of differentiation of a cell to allow gene therapy, stem cell selection or cell cloning.

31. Use of the cDNA of claim 2, for inhibiting methylation in cancel cells using vector mediated gene therapy. --


R E M A R K S

Entry of the amendments to the claims before examination of the application is respectfully requested. These claims have been amended to remove multiple dependencies.

If there are any questions regarding this Preliminary Amendment or this application in general, a telephone call to the undersigned would be appreciated since this should expedite the prosecution of the application for all concerned.

Respectfully submitted,

May 12, 2000

  
J. D. Evans  
Registration No. 26,269

EVENSON, McKEOWN, EDWARDS  
& LENAHA, P.L.L.C.  
1200 G Street, N.W., Suite 700  
Washington, DC 20005  
Telephone No.: (202) 628-8800  
Facsimile No.: (202) 628-8844

Applicant or Patentee: Moshe Szyf et al.  
Serial or Patent No.: \_\_\_\_\_ Atty. Dkt. No.: 1770-183"US-FC  
Filed or Issued: \_\_\_\_\_  
For: DNA DEMETHYLASE, THERAPEUTIC AND DIAGNOSTIC USES THEREOF

**VERIFIED STATEMENT (DECLARATION) CLAIMING SMALL ENTITY STATUS  
[(37 CFR 1.9(f) AND 1.27 (d)) - NONPROFIT ORGANIZATION]**

I hereby declare that I am an official empowered to act on behalf of the nonprofit organization identified below:

NAME OF ORGANIZATION McGILL UNIVERSITY  
ADDRESS OF ORGANIZATION 845 Sherbrooke Street West  
Montréal, Québec, Canada H3A 2T5

TYPE OF ORGANIZATION

- ☒ UNIVERSITY OR OTHER INSTITUTION OF HIGHER EDUCATION  
☐ TAX EXEMPT UNDER INTERNAL REVENUE SERVICE CODE [26 USC 501(a) AND 501(c)(3)]  
☐ NONPROFIT SCIENTIFIC OR EDUCATIONAL UNDER STATUTE OF STATE OF THE UNITED STATES OF AMERICA

(NAME OF STATE \_\_\_\_\_)

(CITATION OF STATUTE \_\_\_\_\_)

- ☐ WOULD QUALIFY AS TAX EXEMPT UNDER INTERNAL REVENUE SERVICE CODE [26 USC 501(a) AND 501 (c)(3)] IF LOCATED IN THE UNITED STATES OF AMERICA

- ☐ WOULD QUALIFY AS NONPROFIT SCIENTIFIC OR EDUCATIONAL UNDER STATUTE OF STATE OF THE UNITED STATES OF AMERICA IF LOCATED IN THE UNITED STATES OF AMERICA

(NAME OF STATE \_\_\_\_\_)

(CITATION OF STATUTE \_\_\_\_\_)

I hereby declare that the nonprofit organization identified above qualifies as a nonprofit organization as defined in 37 CFR 1.9 (e) for purposes of paying reduced fees under section 41(a) or (b) of Title 35, United States Code with regard to the invention DNA DEMETHYLASE, THERAPEUTIC AND DIAGNOSTIC USES THEREOF by inventor(s)

Moshe Szyf; Sanjoy Bhattacharya; and Shyam Ramchandani described in

- ☐ the specification filed herewith  
☐ application serial no. \_\_\_\_\_, filed \_\_\_\_\_  
☐ patent no. \_\_\_\_\_, issued \_\_\_\_\_

I hereby declare that rights under contract or law have been conveyed to and remain with the nonprofit organization with regard to the above-identified invention.

If the rights held by the nonprofit organization are not exclusive, each individual, concern or organization having rights to the invention is listed below\* and no rights to the invention are held by any person, other than the inventor who could not qualify as an independent inventor under 37 CFR 1.9(c) or by any concern which would not qualify as a small business concern under 37 CFR 1.9(d) or a nonprofit organization under 37 CFR 1.9(e).

NOTE: Separate verified statements are required from each named person, concern or organization having rights to the invention averring to their status as small entities. [37 CFR 1.27]

NAME \_\_\_\_\_

ADDRESS \_\_\_\_\_

☐ INDIVIDUAL ☐ SMALL BUSINESS CONCERN ☐ NONPROFIT ORGANIZATION

NAME \_\_\_\_\_

ADDRESS \_\_\_\_\_

☐ INDIVIDUAL ☐ SMALL BUSINESS CONCERN ☐ NONPROFIT ORGANIZATION

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. [37 CFR 1.28(b)]

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this verified statement is directed.

NAME OF PERSON SIGNING Alex Navarre

TITLE IN ORGANIZATION Director - Office of Technology Transfer

ADDRESS OF PERSON SIGNING 845 Sherbrooke Street West, Quebec, Canada H3A 2T5

SIGNATURE  DATE 09/05/2000

09/554414

526 Rec'd PCT/PTO 12 MAY 2000

Attorney Docket: 2055MC/48896  
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: MOSHE SZYF ET AL.

Serial No.: UNASSIGNED

Group Art Unit: UNASSIGNED

Filed: MAY 12, 2000

Examiner: UNASSIGNED

Corresponding to PCT/CA98/01059

November 12, 1998

Title: DNA DEMETHYLASE, THERAPEUTIC AND  
DIAGNOSTIC USES THEREOF

STATEMENT UNDER 37 C.F.R. 1.821(f)


Assistant Commissioner for Patents  
Washington, DC 20231

Sir:

The undersigned hereby states that the contents of the paper copy of the sequence listing in the accompanying U.S. National Stage patent application and the accompanying computer readable copy of the sequence listing are the same.

Respectfully submitted,

May 12, 2000

  
J. D. Evans  
Registration No. 26,269

EVENSON, McKEOWN, EDWARDS  
& LENAHA  
1200 G Street, N.W., Suite 700  
Washington, DC 20005  
Telephone No.: (202) 628-8800  
Facsimile No.: (202) 628-8844  
JDE:dcb



DNA DEMETHYLASE, THERAPEUTIC AND  
DIAGNOSTIC USES THEREOF

BACKGROUND OF THE INVENTION

5 (a) Field of the Invention

The invention relates to a novel enzyme, DNA demethylase, therapeutic and diagnostic uses thereof.

(b) Description of Prior Art

Many lines of evidence have established that  
10 modification of cytosine moieties residing in the dinucleotide sequence CpG in vertebrate genomes is involved in regulating a number of genome functions such as parental imprinting, X-inactivation, suppression of methylation of ectopic genes and differential gene  
15 expression (Szyf, M. (1996) Pharmacol. Ther. 70, 1-37). DNA methylation performs its function of differentially marking genes because the distribution of methylated CpGs is tissue- and site- specific forming a pattern of methylation (Szyf, M. (1996) Pharmacol. Ther. 70, 1-  
20 37). It is clear that the pattern of methylation is fashioned by a sequence of methylation and demethylation events (Brandeis, M. et al. (1993) Bioassays 15, 709-713) during development and is maintained in the fully differentiated cell (Razin, A. et al. (1980) Science 210, 604-610). While it was originally suggested  
25 that DNA demethylation is accomplished by a passive loss of methyl groups during replication (Razin, A. et al. (1980) Science 210, 604-610), it is now clear that an active process of demethylation occurs in embryonal  
30 cells (Frank, D. et al. (1991) Nature 351, 239-241), in differentiating cell lines (Razin, A. et al. (1986) Proc. Natl. Acad. Sci. USA 83, 2827-2831; Szyf, M. et al. (1985) Proc. Natl. Acad. Sci. USA 82, 8090-8094) and in response to estrogen treatment (Saluz, H.P. et  
35 al. (1986) Proc. Natl. Acad. Sci. USA 83, 7167-7171). Two modes of demethylation have been documented: site

specific demethylation that coincides in many instances with onset of gene expression of specific genes and a general genome wide demethylation that occurs during early development *in vivo* during cellular differentiation and in cancer cells (Feinberg, A.P. et al. (1983) Nature 301, 89-92; Razin, A. et al. (1986) Proc. Natl. Acad. Sci. USA 83, 2827-2831). The global demethylation is consistent with the hypothesis that a general demethylase activity which is activated at specific points in development or oncogenesis exists. It has been hypothesized that one mechanism regulating the pattern of methylation is the control of expression of methyltransferase (Szyf, M. (1991) Biochem. Cell Biol. 69, 764-767) and demethylase activities (Szyf, M. (1994) Trends Pharmacol. Sci. 7, 233-238). Although extensive information has been obtained on the enzymatic activity responsible for methylation and the regulation of its expression in the last two decades (Szyf, M. (1996) Pharmacol. Ther. 70, 1-37), the identity of the demethylase has remained a mystery. It is clear however that to fully understand how patterns of methylation are formed and maintained and to determine their role in development, physiology and oncogenesis, one has to identify the demethylase enzyme(s). Two main difficulties have inhibited the identification of this enzyme. First, it is believed that demethylation of a methylated cytosine is chemically highly unlikely since it involves breaking a very stable C-C bond. Second, demethylation occurs at very defined stages in development (Brandeis, M. et al. (1993) Bioassays 15, 709-713) and identifying an adequate tissue source for this enzyme is critical.

Whereas no *bona fide* demethylase has been identified to date, alternative biochemical mechanisms involving exchange of methylated cytosines with non-

methyated cytosines have been described. One previously proposed mechanism is removal of the methylated base by a glycosylase and its replacement with a non-methylated nucleotide utilizing an "excision-repair" mechanism (Razin, A. et al. (1986) Proc. Natl. Acad. Sci. USA 83, 2827-2831). Glycosylase activities that can remove methylated cytosines from DNA have been demonstrated by Vairapandi and Duker (Vairapandi, M. et al. (1993) Nucl. Acids Res. 21, 5323-5327) and more recently by Jost (Jost, J. P. et al. (1995) J. Biol. Chem. 270, 9734-9739). However it is not clear whether this activity is responsible for the general demethylation observed in cellular differentiation. The fact that the activity identified by Jost acts specifically on hemimethylated sequences (which is not the natural substrate in most cases) and can remove thymidines as well as 5-methylcytosines, supports a repair function for this glycosylase-demethylase (Jost, J. P. et al. (1995) J. Biol. Chem. 270, 9734-9739). An alternative mechanism involving a RNA dependent activity has been recently described by Weiss et al. (Weiss et al., 1996). This proteinase-insensitive RNA dependent activity has been shown to catalyze the excision and replacement of a methylated CpG dinucleotide with a nonmethylated CpG dinucleotide that is contained in a DNA-RNA hybrid molecule (Weiss, A. et al. (1996) Cell 87, 709-718). This activity which was identified in differentiating cells in culture was proposed to be involved in demethylation during development. These previous findings demonstrate that the common accepted model in the filed has been that a *bona fide* demethylase does not exist.

It has been previously proposed that the extensive hypomethylation observed in cancer cells might be a consequence of activation of demethylase activity by

oncogenic pathways (Szyf, M.(1994) Trends Pharmacol. Sci. 7, 233-238; Szyf, M. et al. (1995) J. Biol. Chem. 270, 12690-12696). In accordance with this hypothesis we have shown that ectopic expression of v-Ha-ras had  
5 induced demethylation activity in the cells (Szyf, M. et al. (1995) J. Biol. Chem. 270, 12690-12696). Using an assay that directly measures the conversion of 3'<sup>32</sup>P labeled methyl dCMP (mdCMP) into dCMP, we have shown that nuclear extracts prepared from P19-Ras transfectants bear high levels of demethylase activity (Szyf,  
10 M. et al. (1995) J. Biol. Chem. 270, 12690-12696). Building on this observation, we hypothesized that cancer cell lines were a good source for demethylase. However, it is not evident that Ras expression in p19  
15 cells does reflect the situation in cancer cells. P19 is an embryonic cell and expression of Ras might be differentiating them.

It would be highly desirable to be provided with a *bona fide* DNA demethylase (DNA dMTase) to alter  
20 developmental programs for therapeutic and biological use.

#### SUMMARY OF THE INVENTION

In accordance with the present invention, we  
25 demonstrate the purification of a *bona fide* DNA demethylase (DNA dMTase) from a human lung cancer cell line A549, determine its kinetic parameters and substrate specificity. The DNA dMTase activity identified in this study converts methyl-dCMP (mdCMP) residing in the  
30 dinucleotide sequence mdCpG into dCMP whereas the methyl group is released as a volatile residue which was identified to be methanol. The activity is purified away from any trace amounts of dCTP, is insensitive to the DNA polymerase inhibitor ddCTP, is not  
35 affected by the presence of methyl dCTP (mdCTP) in the

reaction and does not exhibit exonuclease or glyco-  
sylase activities. The identification of this new  
enzyme points out to new directions in our understand-  
ing of how DNA methylation patterns are formed and  
5 altered.

One aim of the present invention is to provide a  
*bona fide* DNA demethylase (DNA dMTase).

In accordance with the present invention there  
is provided a DNA demethylase enzyme having about  
10 40 KDa, and wherein the DNA demethylase enzyme is over-  
expressed in cancer cells and not in normal cells.

In accordance with the present invention there  
is provided a cDNA encoding human demethylase which  
comprises a sequence set forth in SEQ ID NO:1.

15 In accordance with the present invention there  
is provided two mouse cDNAs homologous to the human  
cDNA, wherein the cDNA encoding mouse demethylase hav-  
ing a sequence set forth in SEQ ID NOS:5-7.

In accordance with the present invention there  
20 is provided a different human cDNA which encodes a pro-  
tein homologous to the human demethylase having a  
sequence set forth in SEQ ID NO:3.

In accordance with the present invention there  
is provided the use of the expression of demethylase  
25 cDNAs to alter DNA methylation patterns of DNA *in vitro*  
in cells or *in vivo* in humans, animals and in plants.

The demethylase cDNAs expression may be under  
the direction of mammalian promoters, such as CMV.

The demethylase cDNAs expression may be under  
30 plant specific promoters to alter methylation in plants  
and to allow for altering states of development of  
plants and expression of foreign genes in plants.

The demethylase cDNAs expression may be in the  
antisense orientation to inhibit demethylase in cancer  
35 cells for therapeutic processes.

The expression of demethylase cDNA in mammalian cells may be to alter their differentiation state and to generate stem cells for therapeutics, cells for animal cloning and to improve expression of foreign genes.

5 In accordance with the present invention there is provided the use of the expression of demethylase cDNAs in bacterial or insect cells for production of large amounts of demethylase.

10 In accordance with the present invention there is provided the use of the expression of demethylase cDNAs for the production of protein in vertebrate, insect or bacterial or plant cells, such as antibodies against demethylase.

15 In accordance with the present invention there is provided the use of the sequence of demethylase cDNAs as a template to design antisense oligonucleotides and ribozymes.

20 In accordance with the present invention there is provided the use of the predicted peptide sequence of demethylase cDNAs to produce polyclonal or monoclonal antibodies against demethylase.

25 In accordance with the present invention there is provided the use of expression of cDNAs in two hybrid systems in yeast to identify proteins interacting with demethylase for diagnostic and therapeutic purposes.

30 In accordance with the present invention there is provided the use of expression of cDNAs in bacterial, vertebrate or insect cells to produce large amounts of demethylase for obtaining a x-ray crystal structure and for high throughput screening of demethylase inhibitors for therapeutics and biotechnology.

In accordance with the present invention there is provided a volatile assay for high throughput

009060-443900

screening of demethylase inhibitors as therapeutics and anticancer agents which comprises the steps of:

- a) using transcribed and translated demethylase cDNAs *in vitro* to convert methyl-cytosine present in methylated DNA samples to cytosine present in DNA and volatilize methyl group;
- b) determining the absence or minute amount of volatilize methyl group as an indication of an active demethylase inhibitor.

In accordance with the present invention there is provided a volatile assay for the diagnostics of cancer in a patient sample which comprises the steps of:

- a) determining demethylase activity in patient samples by assaying conversion of methyl-cytosine present in methylated DNA to cytosine present in DNA and its volatilization as methyl groups released as methanol;
- b) determining the presence or minute amount of volatilized methyl released as methanol groups as an indication of cancer in the patient sample.

In accordance with the present invention there is provided the use of an antagonist or inhibitor of DNA demethylase for the manufacture of a medicament for cancer treatment, for restoring an aberrant methylation pattern in a patient DNA, or for changing a methylation pattern in a patient DNA.

Such an antagonist is a double stranded oligonucleotide that inhibits demethylase at a  $K_i$  of 50nM, such as  $[C^mGC^mGC^mGC^mG] \cdot [G^mCG^mCG^mCG^mC]_n$ .

The inhibitors include, without limitation an anti-DNA demethylase antibody, an antisense of DNA demethylase or a small molecule such as any derivative of imidazole.

The change of the methylation pattern may activate a silent gene. Such an activation of a silent gene permits the correction of genetic defect such as found for  $\beta$ -thalassemia or sickle cell anemia.

5           The DNA demethylase of the present invention may be used to remove methyl groups on DNA *in vitro* such as needed for cloning DNA.

10           The DNA demethylase of the present invention or its cDNAs may be used, for changing the state of differentiation of a cell to allow gene therapy, stem cell selection or cell cloning.

          The DNA demethylase of the present invention or its cDNAs may be used, for inhibiting methylation in cancer cells using vector mediated gene therapy.

15           In accordance with the present invention there is provided an assay for the diagnostic of cancer in a patient, which comprises determining the level of expression of DNA demethylase by either RT-PCT, ELISA or volatilization assay of the present invention in a  
20           sample from the patient, wherein overexpression of the DNA demethylase is indicative of cancer cells.

#### BRIEF DESCRIPTION OF THE DRAWINGS

25           Figs. 1A to 1B illustrate the purification of demethylase (DNA dMTase) from human A549 cells;

          Figs. 2A and 2C illustrate that DNA dMTase is a protein inhibited by RNA and not by ddCTP, mdCTP;

          Figs. 2B and 2D illustrate the kinetics of DNA dMTase activity;

30           Figs. 3A to 3C illustrate the product of DNA dMTase activity is cytosine and it exhibits no exonuclease or glycosylase activity;

          Figs. 4A-4C illustrate the demethylation reaction releases methanol as a volatile residue;



Fig. 4D illustrates the transfer of a proton from water to regenerate cytosine;

Figs. 4E-4F illustrate that the volatile product is methanol;

5 Fig. 5 illustrates the suggested demethylation reaction;

Figs. 6A-6D illustrate the substrate Specificity of DNA dMTase;

10 Figs. 7A-7D illustrate chromatographic isolation of dMTase from human A549 cells;

Figs. 8A-8B illustrate the alignment between the MDB domain of MeCP2 and demethylase and the predicted amino acid sequence of human demethylase;

15 Fig. 8C illustrates the mRNA encoded by demethylase;

Figs. 9A-9F illustrate the cDNA and their predicted amino acid of demethylases and homologues of the present invention (SEQ ID NOS:1-8);

20 Figs. 10A-B illustrate a mammalian expression vector of dMTase and *in vitro* translated dMTase polypeptide;

Fig. 10C illustrates that *in vitro* translated DNA dMTase releases volatile methyl residues from methylated DNA;

25 Fig. 10D illustrates that *in vitro* translated DNA dMTase transform methylated cytosines to cytosines;

Fig. 11A illustrates that transiently transfected demethylase releases volatile residues from methylated DNA;

30 Fig. 11B illustrates the polypeptide expressed from transiently transfected demethylase;

Figs. 11C-11E illustrate that transiently transfected demethylase transforms methylated cytosines to cytosines in a protein dependent manner;

Fig. 11F illustrates that the transformation of methylated cytosine to cytosine by transiently transfected demethylase depends on the concentration of substrate;

5 Fig. 12A illustrates that transiently transfected demethylase catalyzes the transfer of a proton from tritiated water to regenerate cytosine;

Fig. 12B illustrates that the cloned demethylase releases methanol from methylated DNA;

10 Figs. 13A-13C illustrate that the cancer cells express demethylase activity whereas normal cells do not;

Fig. 13D illustrates that demethylase mRNA is highly express in cancer cells;

15 Fig. 14A illustrates demethylase bacterial retroviral and mammalian expression vector;

Fig. 14B illustrates inhibition of demethylase activity by a specific inhibitor;

20 Fig. 14C illustrates inhibition of tumorigenesis *in vitro* by an inhibition of demethylase;

Fig. 15 illustrates inhibition of tumorigenesis in cell culture by induced expression of demethylase antisense vector;

25 Fig. 16 illustrates the inhibition of demethylase by a small molecule inhibitor imidazole; and

Fig. 17 illustrates a model for the inhibition of cancer growth by an inhibition of demethylase.

#### DETAILED DESCRIPTION OF THE INVENTION

30 The pattern of methylation is fashioned during development by a sequence of methylation and demethylation events. The identity of the demethylase has remained a mystery and alternative biochemical activities have been shown to demethylate DNA but no activity  
35 that can truly remove methyl groups from DNA has been


shown to date. Utilizing human lung carcinoma cells as a source for demethylase activity we demonstrate that mammalian cells bear a *bona fide* DNA demethylase (DNA dMTase) activity. DNA dMTase transforms methyl-C to C by catalyzing replacement of the methyl group on the 5 position of C with a hydrogen derived from water. DNA dMTase demethylates both fully methylated and hemimethylated DNA, shows dinucleotide specificity and can demethylate mdCpdG sites in different sequence contexts. This enzyme is different from previously described demethylation activities: it is proteinase sensitive, activated by RNase and releases different products.

DNA dMTase is a novel enzyme showing a new and unexpected activity that has not been previously described in any organism. The finding of a *bona fide* demethylase, points out new directions in our understanding of the biological role of DNA methylation.

In spite of the fact that it was previously shown that Ras expression in p19 cells can induce demethylation activity. It was not clear whether this demethylation activity is indeed a *bona fide* demethylase. One would predict that demethylase is present in embryonal cells. It was surprising to see that demethylation activity is present in cancer cells. The finding of high levels of demethylase in A549 cells is indeed an unexpected discovery.

In accordance with the present invention, it is shown and demonstrated that demethylation occurs by removal of a methyl group from methylated cytosine in DNA, that a hydrogen from water replaces the methyl group at the 5' position, that the resulting methyl group reacts with the remaining hydroxyl from water to generate methanol which volatilizes (Fig. 4E-F). Thus,

*bona fide* demethylation of DNA involves the following reaction:



5           The cDNA cloned in accordance with the present invention is the demethylase since it can convert methyl-cytosines in DNA to cytosines and volatilize the methyl groups on DNA when transcribed and translated in vitro which are released as methanol. This is a novel  
10 cDNA encoding a biochemical activity that has been not described before.

In accordance with the present invention, there is shown a model for the inhibition of cancer growth by an inhibition of demethylase (Fig. 17).

15

#### **EXPERIMENTAL PROCEDURES**

##### **Cell Culture**

A549 Lung Carcinoma cells (ATCC: CCL 185) were grown in Dulbecco's modified Eagle's medium (with low  
20 glucose) supplemented with 10% fetal calf serum, 2 mM glutamine, 10 U/ml ciprofloxacin. Human Skin Fibroblasts #72-213A MRHF were obtained from BioWhittaker, Bethesda and were grown in Dulbecco's modified Eagle's medium supplement with 2% fetal calf serum, 2 mM glutamine.  
25 H446 Lung carcinoma cells (ATCC: HTB 171) was grown in RPMI 1640 medium with 5% fetal calf serum.

##### **Preparation of nuclear extract**

Nuclear extracts were prepared from A549 cultures at near confluence as previously described (Szyf  
30 et al., 1991; Szyf et al., 1995). The cells were trypsinized, collected and washed with phosphate-buffered saline and suspended in buffer A (10 mM Tris, pH 8.0, 1.5 mM MgCl<sub>2</sub>, 5mM KCl, 0.5% NP-40) at the concentration of 10<sup>8</sup> cells per ml for 10 min. at 4°C. Nuclei were  
35 collected by centrifugation of the suspension at 1000 g

for 10 minutes. The nuclear pellet was resuspended in buffer A (400  $\mu$ l) and collected as described in the experimental procedures. A nuclear extract was prepared from the pelleted nuclei by suspending them in  
5 buffer B (20 mM Tris, pH 8.0, 25% glycerol, 0.2 mM EDTA and 0.4 mM NaCl) at the concentration of  $3.3 \times 10^8$  nuclei per ml and incubating the suspension for 15 min. at 4°C. The nuclear extract was separated from the nuclear pellet by centrifugation at 10,000g for 30 min-  
10 utes. Nuclear extract were stored in -80°C for at least two months without loss of activity.

#### Chromatography on DEAE-Sephadex

A freshly prepared nuclear extract (1 ml , 1.1 mg) was passed through a Microcon™ 100 spin column, the  
15 retainant was diluted to a conductivity equivalent to 0.2 M NaCl in buffer L and applied onto a DEAE-Sephadex column (Pharmacia) (1.0 x 5 cm) that was preequilibrated with buffer L (10 mM Tris-HCl, pH 7.5, 10 mM MgCl<sub>2</sub> ) containing 0.2 M NaCl at a flow rate of 1  
20 ml/min. The column was then washed with 15 ml of the starting buffer (buffer L + 0.2 M NaCl) and proteins were eluted with 5 ml of a linear gradient of NaCl (0.2-5.0 M). 0.8 ml fractions were collected and assayed for demethylase activity after desalting  
25 through a Microcon™ 10 spin column (Amicon) and resuspension of the retainant in 0.8 ml buffer L. DNA demethylase eluted between 2-5.0 M NaCl.

#### Chromatography on S-Sepharose

Active DEAE-Sepharose column fractions were  
30 pooled, adjusted to 0.1 M NaCl by dilution and loaded onto an S-sepharose column (Pharmacia) (1.0 x5 cm) which had been preequilibrated with buffer L containing 0.2 M NaCl at a flow rate of 1 ml/min. Following washing of the column as described in experimental proce-  
35 dures, the proteins were eluted with 5 ml of a linear

NaCl gradient (0.2-5.0M). 0.5 ml fractions were collected and assayed for DNA demethylase activity after desalting and concentrating to 0.2 ml using a Microcon™ 10 spin column. DNA demethylase activity eluted around 5.0 M NaCl.

#### Chromatography on Q-Sepharose

Active fractions from S-sepharose column were pooled, adjusted to 0.2 M NaCl by dilution and applied onto a Q-sepharose (Pharmacia) column (1.0 x5 cm) which had been equilibrated as described in the experimental procedures at a flow rate of 1 ml/min. The column was washed and the proteins were eluted with a linear NaCl gradient (0.2- 5.0 M). Fractions (0.5 ml) were collected, assayed for demethylase activity after desalting and concentrating to a final volume of 0.2 ml as described in the experimental procedures. The demethylase activity eluted around 4.8-5.0 M NaCl.

#### Gel-Exclusion Chromatography on DEAE-Sephacel

The pooled fractions of Q-sepharose column were adjusted to 0.2 M NaCl, loaded onto a 2.0 x 2.0 cm DEAE-Sephacel column (Pharmacia) and eluted with 10 ml of buffer L containing 0.2 M NaCl. The fractions (0.8 ml) were collected and assayed after concentration to about 180 µl with a Microcon™ 10 spin column for DNA demethylase activity. The activity was detected at fraction 4, which is very near the void volume (~200kDa).

#### Assay of DNA demethylase activity

To directly assay DNA demethylase activity in vitro two independent methods were applied.

(A) To assay the conversion of methyl-dCMP (mdCMP) to dCMP we used a previously described method (Szyf et al., 1995). Briefly,  $\alpha^{32}\text{P}$  labeled, fully methylated poly[mdC<sup>32</sup>PdG]n substrate was prepared as follows. One hundred ng of a double-stranded fully methylated

(mdCpdG) oligomer (Pharmacia) were denatured by boiling, which was followed by partial annealing at room temperature. The complementary strand was extended with Klenow fragment (Boehringer Mannheim) using methyl-5-dCTP (mdCTP, 0.1 mM) (Boehringer Mannheim) and [α-<sup>32</sup>P] GTP (100 μCi, 3000 Ci/mmol), and the unincorporated nucleotides were removed by chromatography through a NAP-5 column (Pharmacia). The NAP-5 chromatography was repeated to exclude minor contamination with unincorporated nucleotides. As a control a non-methylated poly[dC<sup>32</sup>pdG]n substrate was similarly prepared except that a nonmethylated dCpdG oligomer served as a template and dCTP was used in the extension reaction. The column fractions (30 μl), described in the experimental procedures were incubated with 1 ng of poly[mdC<sup>32</sup>pdG]n substrate for 1 hour at 37°C in a buffer L containing 25% glycerol (v/v) and 5 mM EDTA. The reacted DNA as well as a nonmethylated poly[dC<sup>32</sup>pdG]n and methylated [mdC<sup>32</sup>pdG]n nonreacted controls were purified by phenol/chloroform extraction and subjected to micrococcal nuclease digestion (100 μg at 10 μl) and calf spleen phosphodiesterase (2μg) (Boehringer) (Pharmacia) to 3' mononucleotides for 15 hours at 37°C. The digestion products were loaded onto a thin layer chromatography plate (TLC) (Kodak, 13255 Cellulose), separated in a medium containing, 132 ml Isobutyric acid:40 ml water: 4 ml ammonia solution, autoradiographed and the intensity of the different spots was determined using a phosphorimager (Fuji, BAS 2000). <sup>32</sup>P labeled substrates and tritium labeled substrates were phosphoimaged using BAS 2000 plate and BAS-TR2040 phosphorimager plate respectively.

(B) The second method determined removal of methylated residues from methylated DNA by measuring disappearance of <sup>3</sup>H-CH<sub>3</sub> or <sup>14</sup>C-CH<sub>3</sub> from the reaction mixture. 100 ng

of poly [dCdG]n double stranded DNA was methylated using SssI methylase (New England Biolabs) and an excess of [<sup>3</sup>H-methyl AdoMet (80 Ci/mmol; New England Nuclear)]. The tritiated methyl group containing DNA was purified from labeled AdoMet using NAP-5 column chromatography. All column purified fractions of DNA demethylase were assayed using the tritiated substrate. In a typical assay, 1 ng of DNA was incubated (at a specific activity of 4 x10<sup>6</sup>dpm/mg) with 30 µl of column fraction for one hour at 37°C in buffer L. To determine the number of methyl groups remaining in the DNA following incubation with the different fractions, 250 µl of water were added and the mixture was incubated at 65°C for 5 minutes. One hundred µl of the reaction mixture were withdrawn for liquid scintillation counting. Controls received similar treatment except that in place of a column fraction, an equal volume of buffer L was added. The number of methyl groups that were removed from the DNA by the different fractions was determined by subtracting the remaining counts in each of the fractions from the counts remaining in the control. All tests were carried out in triplicates. The results are presented as picomole methyl group removed. One unit of DNA dMTase activity is defined as: amount of enzyme that releases one picomole of methyl group from methylated dCpdG substrate in one hour at 37°C.

#### **Methyl removal assay using double-labeled substrates**

To determine whether the methyl group leaves the DNA and not any non-specific removal of tritium, we prepared SK plasmid DNA containing a tritiated hydrogen at the 6' position of cytosine and thymidine by growing the plasmid harboring bacteria in the presence of deoxy [6-<sup>3</sup>H] Uridine (22 Ci/mmol; Amersham) (10µCi/ml). The [6-<sup>3</sup>H]-cytosine containing pBluescript SK(+) was puri-



fied according to standard protocols and was methylated using an excess of [ $^{14}\text{C}$ -methyl] AdoMet (59 mCi/mmol; Amersham) (10  $\mu\text{Ci}$  per 100  $\mu\text{l}$  reaction) and SssI methylase. The double labeled DNA substrate was purified  
5 twice on a NAP-5 column. 15  $\mu\text{l}$  of DNA dMTase were incubated with 1 ng of double labeled DNA (specific activity of 2000 dpm/ng) for 1 hour at 37°C. Following incubation, the remaining  $^{14}\text{C}$  versus  $^3\text{H}$  counts were determined as described in the experimental procedures  
10 by scintillation counting (Wallac). The  $^{14}\text{C}$  counts were normalized against  $^3\text{H}$  counts. The controls received similar treatment except that instead of DNA dMTase, an equal amount of distilled water was added to them.

To determine the number of  $^3\text{H-CH}_3$  in the gaseous  
15 phase, 1 ng of  $^3\text{H-CH}_3$  poly [dCpdG] DNA were incubated with DNA dMTase overnight in a sealed tube (Pierce, Illinois, USA). 0.8 ml of air were removed from the tube using a gas tight syringe (Hamilton, Reno, Nevada) and injected into a sealed gas tight scintillation vial  
20 containing 10 ml OptiPhase scintillation fluid (Wallac, UK) and counted. As a control the DNA was incubated with an equal volume of buffer L and treated similarly.

#### Synthesis of other methylated dC dinucleotides

Poly [mdC $^{32}\text{pdA}$ ] and [mdC $^{32}\text{pdT}$ ] substrates were  
25 prepared as follows. About 0.5  $\mu\text{g}$  of 20 mer oligonucleotides 5'(GG)103', 5'(GT)103' and 5'(GA)103' were boiled and annealed at room temperature with oligonucleotide 5'CCCCC3', 5'CACACA3' and 5'CTCTCT3' respectively. The complementary strand was extended with  
30 Klenow fragment using m5dCTP (Boehringer Mannheim) and either [ $\alpha^{32}\text{P}$ ] dATP (100 $\mu\text{Ci}$ , 3000Ci/mmol) or [ $\alpha^{32}\text{P}$ ] dTTP (100  $\mu\text{Ci}$ , 3000 Ci/mmol) respectively. The unincorporated nucleotides were removed by chromatography through a NAP-5 column. Hemimethylated mdCpG substrate  
35 was prepared in a similar manner except that a nonmeth-

ylated poly dCpdG substrate (Boehringer) was used as template and m5dCTP and [ $\alpha^{32}\text{P}$ ]dGTP were used for extension as described in the experimental procedures.

#### Assay for nuclease and glycosylase activity

5            [ $^{32}\text{pmdCpdG}$ ]n substrate which included a labeled  
           $^{32}\text{P}$  5' to mdC was prepared as follows. About 100 ng of  
poly dCpdG DNA were boiled and partially annealed at  
room temperature. [ $\alpha^{32}\text{P}$ ]dCTP and cold dGTP were used for  
complementary strand extension as described in the  
10        experimental procedures. The free nucleotides were  
separated using NAP-5 column chromatography. The purified  
          [ $^{32}\text{pmdCpdG}$ ]n DNA was subjected to methylation by  
SssI methylase using 320  $\mu\text{M}$  AdoMet. The DNA was repurified  
twice using a NAP-5 column. The methylated DNA (1  
15        ng) was incubated with either 30  $\mu\text{l}$  DNA dMTase, nuclear  
extract or buffer L. To determine whether  $\alpha^{32}\text{P}$  labeled  
residue is excised from the DNA it was directly applied  
(3 $\mu\text{l}$ ) onto a TLC plate. To determine whether the DNA  
was demethylated it was subjected to digestion with  
20        snake venom phosphodiesterase (0.2 mg in a 10 $\mu\text{l}$  reac-  
tion volume) (Boehringer Mannheim) which attacks the  
3'-OH group releasing 5'-mononucleotides. The result-  
ing mononucleotides were separated on TLC plates and  
autoradiographed.

25            To test whether dCTP copurifies with DNA dMTase,  
which may be involved in activities other than bona  
fide demethylation, 20  $\mu\text{M}$  of dCTP with 1  $\mu\text{l}$  of  $\alpha^{32}\text{P}$   
labeled dCTP (3000 Ci/mmol) was loaded onto the column  
with nuclear extract. The  $^{32}\text{P}$  counts were measured in  
30        the flow through, washes and in the different frac-  
tions. About 1.1 million counts were loaded onto the  
DEAE-Sepharose column and were all recovered up to  
fraction 8.

          To determine whether DNA dMTase contains a DNA  
35        polymerase activity, DNA demethylase reactions were

performed in presence of 500  $\mu$ M of ddCTP (Pharmacia) or 500  $\mu$ M of m5dCTP (Boehringer Mannheim) at initial rate conditions.

To determine whether DNA dMTase is sensitive to RNase or Proteinase K treatment, DNA dMTase was pre-treated for 1 h at 56°C with 200  $\mu$ g/ml proteinase K (Sigma). A demethylation reaction was carried out with this pretreated fraction in the usual manner using both demethylation assays described in the experimental procedures. To test the effect of RNA digestion on the demethylation reaction, the fractions from different columns were treated with 100  $\mu$ g/ml RNase A (Sigma).

#### **Demethylation of pBluescript SK(+) Plasmid**

About 4  $\mu$ g plasmid pBluescript SK (Stratagene) was subjected to methylation using SssI methylase. The methylated plasmid (4 ng) was incubated with 30  $\mu$ l of DNA dMTase Fraction 4 of DEAE-Sephacel column under standard conditions, extracted with phenol: chloroform and precipitated with ethanol. About 1 ng of the plasmid were subjected to digestion with 10 units each of either of the restriction endonucleases EcoRII (GIBCO-BRL), DpnI, HhaI or HpaII (New England Biolabs) before and after methylation as well as after DNA dMTase treatment in a reaction volume of 10  $\mu$ l for 2 hour at 37°C. Following restriction digestion the plasmids were extracted with phenol:chloroform, ethanol precipitated and resuspended in 10  $\mu$ l. The plasmids were electrophoresed on a 0.8% (w/w) Agarose gel, transferred onto a Hybond Nylon membrane and hybridized with pBluescript SK(+) plasmid which was  $^{32}$ P labeled by random-priming (Boehringer Mannheim).

#### **Effect of Redox Reagents (NAD, NADH, NADP, NADPH and FeCl<sub>3</sub>) on demethylase activity**

The reagents were prepared at 100  $\mu$ M concentration and added at a final concentration of 10  $\mu$ M to a standard methyl removal assay under initial rate condi-

tions as described in the experimental procedures. The methyl removal activity in presence of each of the cofactors was compared to a control DNA dMTase reaction.

5 **Determination of kinetic parameters**

For determination of kinetic parameters, the demethylation reactions were performed using both assays (generation of dCMP and removal of methyl) as described in the experimental procedures except that  
10 varying DNA concentrations from 0.1 nM to 2.5 nM were used in a total volume of 50  $\mu$ l including 30  $\mu$ l of DNA dMTase. Since it has been established by previous experiments that the reaction proceeds for at least 3 hours, the initial velocity of reaction was measured  
15 at one hour intervals. The velocity data was collected at each substrate DNA concentration range stated for both assays. The  $K_m$  and  $V_{max}$  values for DNA demethylase activity were determined from double reciprocal plots of velocity versus substrate concentration.

20 **Measurements of methanol production catalyzed by demethylase by gas chromatography**

Gas chromatography was performed with a Varian<sup>TM</sup> model 3400 GC equipped with a 30m Stabilwax<sup>TM</sup> column (0.053 cm i.d.: Restek Corporation). Nitrogen<sup>TM</sup> was  
25 used as carrier gas at a flow rate of 32 ml/min, the injector and detector chambers were at 200 and 300°C respectively. The column was maintained at 40°C for 5 minutes after sample injection.

The demethylase reaction was performed in eppendorf tubes kept within sealed scintillation vials with  
30 300  $\mu$ l of water as aqueous phase (in radioactive trapping experiments this was replaced by 300  $\mu$ l of methanol). The demethylase reaction was initiated in buffer L (10 mM  $MgCl_2$ , 10 mM Tris-HCl pH 8.0) with 500 ng of  
35 tritiated SK plasmid (6000 dpm/ $\mu$ l) and 100  $\mu$ l of demethylase at 37°C. After overnight incubation at 37°C,

the aqueous phase surrounding the eppendorf tube was transferred to a fresh eppendorf tube, 2  $\mu$ l of this mixture was injected in the gas chromatography using a gas tight syringe (Hamilton, Reno, Nevada).

5 **Coupled in vitro transcription translation**

The mRNAs encoded by the pCDNA 3.1/His Xpress demethylase constructs described above were transcribed and translated by coupled transcription-translation using Promega<sup>TM</sup> TNT reticulocyte lysate kit (according  
10 to manufacturer's protocol), 2  $\mu$ g of each construct and 40 $\mu$ Ci of [<sup>35</sup>-S]methionine (1,000Ci/mmol, Amersham) in a 50 $\mu$ l reaction volume. To purify non labeled in vitro translated demethylase, coupled in vitro transcription and translation was performed as above but in the pres-  
15 ence of cold methionine. The translation products were bound to a Probond<sup>TM</sup> nickel column (Invitrogen) and demethylase was eluted according to the manufacturer's protocol with increasing concentrations of imidazole. Demethylase is eluted at 350-500mM imidazole. The imi-  
20 dazole eluted demethylase was dialyzed and concentrated by lyophilization.

25 **Gas chromatography coupled with Mass spectrometry (GC-MS) Analyses for identification of volatile product of demethylase catalyzed reaction as methanol**

The demethylation reactions (volume 50 l) were run in conical vials having a total internal volume of 350 microlitres. The vials were closed with a teflon-lined screw cap and left at room temperature for 18 h.  
30 The vials were cooled in an ice bath, opened and 10 mg of NaCl and 50 microlitres of toluene were added. The vials were frequently shaken over a period of 1 h. The toluene phases were pipetted into clean vials in a manner to rigorously exclude water carry over. Anhydrous  
35 sodium sulfate (5 mg) was added to the toluene extracts to remove water, and the toluene phases were pipetted

into autoinjector vials for GC/MS analysis. Aliquots of 3 microlitres were analyzed under the following instrumental conditions: Instrument: Hewlett-Packard 5988A; Column: 30 m x 0.25 mm i.d. fused quartz capillary with 0.25 micron DB-1 liquid phase, programmed after an initial hold for 1 min at 70 deg at 5 deg/min to 80 deg, then ramped ballistically to 280 deg for bake-out for 5 min; Injector and interface temperatures: 250 deg; Helium flow rate 1.5 ml/min; Mass spectrometer: ion source 200 deg, 70 eV electron impact ionization, scanning from m/z 10 to 50 in full scan mode was begun 6 s after injection, and ceased at 1.5 min to avoid acquisition of the intense toluene solvent peak.

Human A549 cells bear a demethylase activity that could be purified away from dCTP and DNA MeTase

The use of an appropriate cellular source and a direct assay for demethylase activity are obviously critical. As we have previously shown that demethylase activity was induced in response to ectopic expression of the Ras oncogene (Szyf et al., 1995) we reasoned that cancer cells might bear high levels of demethylase activity. Based on preliminary studies demonstrating the presence of high levels of demethylase activity in the human lung carcinoma cell line A549, we have chosen this cell line for our further studies and purification steps. Previous studies have used indirect measures such as increased sensitivity to methylation-sensitive restriction enzymes as indicators of demethylase activity (Weiss et al., 1996; Jost et al., 1995). To directly measure the conversion of 5-mdCMP in DNA to dCMP, we have utilized a completely methylated <sup>32</sup>P labeled [mdC<sup>32</sup>pdG]n double stranded oligomer which we had previously described (Szyf et al., 1995). Following incubation with the different fractions, the

DNA is purified and subjected to cleavage with microco-  
cal nuclease to 3' mononucleotides. The 3' labeled  
mdCMP and dCMP are separated by thin layer chromatogra-  
phy (TLC) and the conversion of mdCMP to dCMP is  
5 directly determined. This assay provides a stringent  
test for *bona fide* demethylation and discriminates it  
from previously described 5mCpC replacement activities  
(Jost et al., 1995; Weiss et al., 1996). The glyco-  
sylase-demethylase activity described by Jost et al.  
10 (Jost et al., 1995) will require the presence of a  
ligase activity and an energy source for replacement of  
mdC with C to be detected by our assay, whereas the  
demethylase activity described by Weiss et al. will not  
be detected since it replaces the intact mdC<sup>32</sup>pdG dinu-  
15 cleotide with a cold dCpdG without altering its state  
of methylation (Weiss et al., 1996).

Nuclear extracts were prepared from A549 cells,  
applied onto a DEAE-Sephadex column, eluted with a lin-  
ear gradient from 0.2-5.0M NaCl and the fractions were  
20 assayed for demethylase (dMTase) activity as described  
in the experimental procedures. As shown in Fig. 1(A)  
a clear peak of dMTase activity is eluted at the high  
salt fraction 10.

Conversion of methylated cytosine to cytosine:  
25 Nuclear extracts prepared from A549 cells (1.1 mg) were  
passed through an AMICON™ 100 spin column. The retain-  
ant (98.56 mg, 0.2 mg/ml) was loaded onto a DEAE-Sepha-  
rose column, the different chromatographic column frac-  
tions eluted by a linear NaCl gradient (0.2-5M) were  
30 desalted and (30 µl) incubated with 1 ng of [mdC<sup>32</sup>pdG]n  
double stranded oligomer for 1 hour at 37°C, digested  
to 3' mononucleotides and analyzed on TLC as described  
in the experimental procedures. Control methylated  
(ME) and nonmethylated (NM) [dC<sup>32</sup>pdG]n substrates were  
35 digested to 3' mononucleotides and loaded on the TLC

plate to indicate the expected position of dCMP and mdCMP. The active fraction is indicated by an arrow. This fraction was loaded on S-Sepharose followed by Q-Sepharose and DEAE-Sepharose fractionation.

5 The first chromatography step purified the dMTase activity from the bulk of nuclear protein (Fig. 1B) and is a very effective purification step.

DNA dMTase activity as measured by the release of volatile methyl residues. The different column  
10 fractions were incubated with 1ng ( $4 \times 10^6$  dpm/ $\mu$ g) of [ $^3$ H]-CH<sub>3</sub>-[mdCpdG]n oligomer and the release of volatile methyl residues was determined (-) and presented as total dpm). The results are an average of three independent determinations. Protein concentration was  
15 determined using the Bio-Rad Bradford kit (-). The elution profile of 20  $\mu$ M of [ $^{32}$ P]- $\alpha$ -dCTP incubated with the protein was determined by scintillation counting of the different DEAE fractions (-) and presented as fraction of dCTP loaded on the column.

20 To exclude the possibility that the DNA dMTase activity detected in our assay is carried by the DNA MeTase, we assayed the fractions for DNA MeTase activity using a hemimethylated DNA substrate as previously described (Szyf et al., 1991). As observed in Figure  
25 1B DNA MeTase activity is detected in the second and third fractions, thus our fractionation separated DNA dMTase away from the DNA MeTase suggesting that they are independent proteins.

There is a remote possibility that the demethylation observed is not a *bona fide* demethylation but  
30 a consequence of a glycosylase removal of mC, followed by removal of the remaining deoxyribose-phosphate by AP (apyrimidine) nuclease, repair of the gap catalyzed by DNA polymerase using trace dCTP contained in the fraction  
35 tion and ligation of the break with ligase in the pres-



ence of residual ATP. For this hypothesis to be consistent with our data, four independent enzymes and two cofactors have to cofractionate with DNA dMTase. To exclude the possibility that a trace amount of dCTP is bound to DNA dMTase active fraction, we have added 20  $\mu$ M of  $^{32}$ P labeled dCTP ( $10 \times 10^6$  cpm) to the nuclear extract and determined its elution profile on the DEAE column. Less than background cpm (10 cpm) were detected in the DNA dMTase active fraction suggesting that our first column purifies dCTP away from the DNA dMTase at least  $1 \times 10^6$  fold (Fig. 1B). If any dCTP is present in the nuclear extract, the remaining concentration after fractionation on DEAE is well below the Kms of the known DNA polymerases. The possibility that dCTP is so tightly bound to the enzyme that it could not be replaced by the exogenous  $^{32}$ P labeled dCTP is very remote since an enzyme using dCTP as substrate must readily exchange dCTP.

The active fraction 10 was further fractionated sequentially on the following columns: S-Sepharose and Q-Sepharose. The DNA dMTase eluted at the high salt fraction from both columns as determined by the [mC $^{32}$ pdG]n demethylation assay (Fig. 1A). The ion exchange chromatography was followed by chromatography on DEAE-Sephacel.

The fact that we have maintained our activity even after 4 fractionation steps (Table 1) and that only a single polypeptide is apparent after the last purification step argues strongly against the possibility that the activity detected in our study is a repair or replacement activity. Any replacement mechanism must involve a number of proteins and additional cofactors and substrates. In summary, the chromatography of the demethylase activity in A459 cells provides strong

support to the hypothesis that mammalian cells bear a *bona fide* demethylase activity.

**DNA dMTase releases a volatile derivative**

A *bona fide* demethylation has to result in  
5 release of the methyl group as a volatile derivative  
such as CO<sub>2</sub>, methanol, methane or formaldehyde. We  
have therefore incubated a {[<sup>3</sup>H] -CH<sub>3</sub>-dCpdG}<sub>n</sub> double  
stranded oligonucleotide with the different column  
fractions and the rate of release of the tritiated  
10 methyl from the aqueous phase was determined by scin-  
tillation counting of the remaining radioactivity in  
the reaction mix. As demonstrated in Fig. 1b (dia-  
mond), the dMTase active fractions release labeled  
methyl groups from the methylated substrate.

15 **DNA dMTase is a protein which is inhibited by RNA, does  
not involve an exchange activity and does not require  
additional cofactors**

DNA dMTase activity measured either as transfor-  
20 mation of mdC to C (Fig. 2a) or as release of volatile  
methyl residues (Fig. 2c) is abolished after proteinase  
K treatment and is not inhibited but rather enhanced  
following RNase treatment. 500 μM of ddCTP which  
inhibits DNA polymerase does not inhibit demeth-  
25 ylation of the [mdC32pdG]<sub>n</sub> substrate, nor is it inhib-  
ited by high concentrations of methyl-dCTP (500 μM)  
(Fig. 2a), which is consistent with the hypothesis that  
demethylation does not involve an excision and replace-  
ment mechanism. If a replacement mechanism is involved  
30 in demethylation, the presence of mdCTP should result  
in incorporation of methylated cytosines and essential  
inhibition of demethylation. Thus, the DNA dMTase  
identified here is a protein and not an RNA and is une-  
quivocally different from the previously published RNA  
35 based or glycosylase based demethylase activities.

The DNA dMTase reaction proceeds without any requirement for additional substrates such as dCTP, redox factors such as NADH and NADPH or energy sources such as ATP (data not shown). As observed in Fig. 2b and 2d, the DNA dMTase reaction maintains its initial velocity up to 90 minutes and continues up to 120 minutes. This time course is inconsistent with dependence on enzyme-bound additional nonreplenishable substrates such as dCTP or ATP or a nonreplenishable redox factor such as NADH or NADPH. Exhausting the nonreplenishable substrate or redox factor would have resulted in rapid deceleration of the initial velocity.

**A product of the demethylation reaction is deoxyCytosine in DNA**

What is the product of the demethylation reaction? The results presented above (Fig. 1a, 2a and b) based on a one dimension TLC separation show that DNA dMTase generates dC from mdC in DNA. To further substantiate this conclusion, we subjected DNA dMTase treated DNA to remethylation with the CpG MeTase M.Sss I which can transfer a methyl group exclusively to dC. The results presented in Fig. 3a show that the demethylated product of DNA dMTase is dC since it is completely remethylated with M.Sss I. The identity of the demethylated product as dC was further established by a two-dimension TLC analysis demonstrating that the product of dMTase comigrates with a cold dCMP standard in both dimensions (Fig. 3b).

DNA dMTase does not release a nucleotide, a phosphorylated base or phosphate from methylated DNA when incubated with a [<sup>32</sup>pmdCpdG]<sub>n</sub> substrate which included a labeled 32P 5' to mdC or our standard methylated substrate (Fig. 1) where 32P is 3' to the m5dC (Fig. 3c). Nuclear extracts which obviously contain a number of glycosylases and nucleases release phospho-

rylated derivatives in the same assay (Fig. 3c). dMTase transforms the methyl cytosine in the [32pmdCpdG]n substrate to cytosine as demonstrated when the reacted DNA is digested to 5' mononucleotides (Fig. 3c +V PDS) and analyzed by TLC. Since this reaction does not involve release of a 32P derivative (Fig. 3c -V PDS), it demonstrates that dMTase transforms methylated cytosines to cytosines on DNA without disrupting the integrity of the DNA substrate by glycosylase or nuclease activity .

**The second product of the dMTase reaction is methanol**

What is the identity of the leaving group? The results presented in Fig1b suggest that the labeled methyl leaves the DNA as a volatile compound. The demethylase reaction involves release of the methyl group *per se* whereas the cytosine base ring remains in the aqueous phase. Fig. 4a demonstrates this point by using a methylated plasmid labeled with a <sup>3</sup>H-hydrogen at the sixth position of cytosine and [14C]-methyl at the fifth position of cytosine as a substrate.

The three most obvious candidates the methyl group is leaving as are formaldehyde, carbon dioxide, and methanol. Methadone trapping for labeled formaldehyde detection and sodium hydroxide trapping for labeled carbon dioxide detection were both negative in identifying the form in which the methyl group is leaving in the dMTase reaction (data not shown). The other possible chemical form that the methyl group may leave the DNA as, is methanol. Since methanol is a volatile compound, a simple method to measure generation of methanol is a scintillation-volatilization assay (see Fig. 4b for description). Volatilization assays have been previously used to measure release of methanol in demethylation reactions. The demethylation reaction mix containing the labeled {[<sup>3</sup>H] -CH<sub>3</sub>-dCpdG}n substrate

with either dMTase or no enzyme, as a control, is added to an uncapped 0.5 ml tube which is placed in a sealed scintillation vial containing scintillation fluid. Released methanol is volatile, diffuses out of the open  
5 reaction tube and is mixed with the excess of the scintillation fluid in the vial registering as counts in the scintillation counter. As a control indicating that methanol is volatilized under the conditions of our assay, we incubated approximately equal counts of  
10 radioactively labeled methanol under the same conditions and measured the counts in a scintillation counter at different time points. As observed in Fig. 4c the majority of methanol in the reaction tube volatilizes from the reaction tube into the scintillation  
15 fluid following an overnight incubation at 37°C. The experiment shown in Fig. 4b demonstrates that volatilized label is released from methylated DNA only in the presence of dMTase.

The identity of the volatile group has been  
20 determined to be methanol by a gas chromatography (GC) analysis. The demethylation and control reactions (indicated in Fig. 4e) were performed in an uncapped tube placed in a sealed scintillation vial containing a larger volume (300 $\mu$ l) of water. The volatile residue  
25 diffuses into the surrounding water and mixes with it. A 2  $\mu$ l sample of the surrounding water was injected into a GC column as described in the methods. As shown in Fig. 4e, the volatile compound released by dMTase in a dose response manner coelutes with metha-  
30 nol. Release of methanol is observed only in the presence of both dMTase and methylated DNA. No methanol is released when dMTase is reacted with nonmethylated DNA, demonstrating that methanol is a product of demethylation of DNA.

The leaving group was also identified as methanol using gas chromatography coupled with Mass spectrometry (GC-MS). As illustrated in Fig. 4f., incubation of methylated DNA with dMTase (dMTase+ME-DNA) results in release of a peak with the retention time and mass spectrum (peaks are identified at 32 and 29 atomic mass which are the atomic masses of methanol and ionized methanol respectively) which is consistent with its identification as methanol. Incubation of dMTase with nonmethylated DNA does not release methanol indicating that methanol is a product of the demethylation reaction. No methanol is released when the samples are incubated with dMTase treated with protease K indicating that the release of methanol from methylated DNA is catalyzed by an enzymatic activity.

**Demethylation involves transfer of a hydrogen from water to regenerate cytosine**

If demethylation involves removal of the methyl moiety from mdC, a hydrogen has to be transferred to the carbon at the 5' position to regenerate cytosine. Since no redox factors are involved, what is the source of the hydrogen? To test the hypothesis that the source of the hydrogen is water, we incubated either non labeled [mdCpdG]n or [dCpdG]n double stranded DNA with DNA dMTase for different time periods in the presence of tritiated water, following which the DNAs were digested to 3' dNMPs, separated on TLC with non-radioactive standards for each of the 5 possible dNMPs and exposed to a tritium sensitive phosphorimaging plate. As seen in Fig.4d, dMTase catalyzes the transfer of a tritiated hydrogen from water to dCMP in methylated DNA in a time dependent manner only when methylated DNA is used as a substrate. Based on the experiments described in Fig.3 and 4 we propose that dMTase catalyzes the exchange of the methyl group at

the 5' position of cytosine in DNA with hydrogen from water and the methyl group reacts with the remaining hydroxyl group to form methanol (Fig. 5).

#### 5 Substrate and sequence specificity of DNA dMTase

Methylation of CpG dinucleotides is the most characterized modification occurring in genomic DNA<sup>8,48</sup>. The results presented in Fig.6 demonstrate that DNA dMTase is a general DNA dMTase activity that demethylates fully or hemimethylated dCpdG in DNA flanked by a variety of sequences which are distributed at different frequencies, but does not demethylate methylated adenines or methylated cytosines that do not reside in the dinucleotide CG. First, as shown in Fig.6a, a plasmid DNA methylated *in vitro* at all dCpdG sites with M.Sss I and all d\*CdCdGdG sites with M. Msp I (which methylates the external C in the sequence \*CCGG, thus enabling the determination of demethylation at the CC dinucleotide) and *in vivo* with the *E. coli* DCM MeTase at dCmCdA/dTdGdG sites and with the DAM MeTase at dGmdAdTdC sites (adenine methylated) was treated with dMTase and the state of methylation of the plasmid was determined using the indicated methylation sensitive restriction enzymes. dMTase demethylates C\*G methylated sites as indicated by the sensitivity of the dMTase treated plasmid to *Hpa* II and *Hha* I but does not demethylate C\*C, C\*A or C\*T methylated sites as indicated by the resistance to *Msp* I and *Eco* RII restriction enzymes, or adenine methylation as indicated by its sensitivity to *Dpn* I. Second, bisulfite mapping analysis of methylation of 5 methylated C\*G sites residing in a M.Sss I *in vitro* methylated pMetCAT plasmid following dMTase treatment shows that all C\*G sites are demethylated irrespective of their flanking sequences thus excluding the possibility that demethylation is limited to CCGG or CGCG sequences (Fig. 6b).

Third, dMTase does not demethylate two fully methylated cytosine bearing oligomers [dmC32pdA]n, [mdC32pdT]n demonstrating that mdCpdA and mdCpdT are not demethylated by DNA dMTase (Fig. 6d). Fourth, dMTase demethylates a hemimethylated synthetic substrate [dCpdG]n\*[mdC32pdG]n (Fig. 6d). Demethylation of SK is complete under these conditions (Fig. 6a) whereas demethylation of a methylated [mdCpdG]n substrate is not complete under the same conditions (Fig. 6d). This can reflect differences in the sequence composition of the substrate and the frequency of methylated cytosines. The [mdCpdG]n contains on average 16 fold more methylated cytosines per molecule than plasmid DNA. Alternatively, these differences might reflect discrepancies in the assays used, restriction enzyme digestion versus a nearest neighbor analysis. To address this discrepancy we have labeled a fully methylated SK plasmid with [ $\alpha^{32}$ P]dCTP, 5-methyl-dCTP and the other dNTPs, subjected it to dMTase treatment and digested it to mononucleotides at different time points following the initiation of the reaction and subjected the samples to a TLC analysis. As shown in Fig. 6c, the SK plasmid is fully demethylated at 3 hours which is consistent with the results obtained with methylation sensitive restriction enzymes (Fig. 6a).

The  $K_m$  of DNA dMTase for hemimethylated and fully methylated DNA was determined by measuring the initial velocity of the reaction at different concentrations of substrate (Table 2). The calculated  $K_m$  for hemimethylated DNA is 6 nM which is two fold higher than the  $K_m$  for DNA methylated on both strands, 2.5-3 nM (Table 2). It is unclear yet whether this small difference in affinity to the substrate has any significance in a cellular context. Thus similar to the DNA MeTase DNA dMTase shows dinucleotide sequence



selectivity but in difference from DNA MeTase which shows preference to hemimethylated substrates dMTase prefers fully methylated DNA which is consistent with a role for DNA dMTase in altering established methylation patterns.

Table 1

Purification of DNA dMTase

Purification step	Total protein ( $\mu$ g)	Total dpm	pMole/ $\mu$ g	pMole/ $\mu$ g/h	Fold Purification
Nuclear extract	6000	1107.2	$5.5 \times 10^{-5}$	$1.833 \times 10^{-5}$	-
DEAE-Sephadex	3.75	5844	0.4674	0.156	8445.5
SP-Sepharose	0.77	5106	1.989	0.663	35939.84
Q-Sepharose	0.46	5335	3.4	1.13	62860.65
DEAE-Sepharcel	0.018	1834	30.57	10.19	552243.2

Table 2

Kinetic parameters for DNA dMTase

Method	$K_m$ (DNA)	$V_{max}$ (pMole/h)
Methylated oligo CpG	2.5 nM	340
Hemi-methylated CpG	6.0 nM	402
Methylated SK-DNA	3.3 nM	40.42

**Cloning and construction of demethylase expression vectors**

**15 PCR amplification of the MBD domain of the putative demethylase candidate cDNA**

One  $\mu$ g of total RNA prepared from the human small lung carcinoma cell line A549 was reverse transcribed using Superscript reverse transcriptase and random primers (Boehringer) in a 25  $\mu$ l reaction volume according to conditions recommended by the manufacturer (GIBCO-BRL). Five  $\mu$ l of reverse transcribed cDNA were subjected to an amplification reaction with Taq polymerase (Promega, 1 unit) using the following set of

primers: sense 5'CTGGCAAGAGCGATGTC 3' SEQ ID NO:9,  
antisense 5'AGTCTGGTTTACCCTTATTTTG 3' SEQ ID NO:10.

Amplification conditions were: step 1. 95°C 1 min.; step 2: 94°C 0.5 min; step 3: 45°C 0.5 min.; step  
5 4: 72°C 1.5 min; steps 2-4 were repeated 30 times.  
MgCl<sub>2</sub> was adjusted to 1 mM according to conditions recommended by the manufacturer. The PCR products were  
cloned in pCR2.1 vector (Invitrogen) and the sequence  
of the cDNAs was verified by dideoxy-chain termination  
10 method using a T7 DNA sequencing kit (Pharmacia). The  
amplified fragment was excised from the plasmid with  
EcoRI, labeled with a Boehringer random prime labeling  
kit according to manufacturer's protocol and alpha <sup>32</sup>P-  
dCTP. The labeled probe was used to screen a HeLa cell  
15 cDNA library in λTriplEx phage (Clontech) according to  
standard procedures. Positive clones were identified  
and further purified by serial dilutions for 4 rounds.  
The insert in the pTriplEx plasmid was excised from the  
phage according to manufacturer's protocols and the  
20 identity of the insert was verified by sequencing. The  
insert was excised by NotI restriction and subcloned  
into either the inducible expression vector: Retro tet  
on (Clontech) in the sense and antisense orientation or  
the pcDNA3.1/His Xpress vector in all three frames and  
25 in the antisense orientation.

#### **Transfection and expression of demethylase in vertebrate cells**

Ten µg of either Retro tet on demethylase or  
30 pcDNA 3.1/His Xpress demethylase are mixed with 8 µl of  
transfection lypophilic reagent Pfx-2 (Invitrogen) and  
placed upon 100,000 mouse (3T3 Balb/c, human (A549) or  
monkey cells (CV-1) according to manufacturer's proto-  
col in OPTIMEM medium for 4 hours. Cells are harvested  
35 after 48 hours and demethylation and demethylase activ-  
ity is determined by measuring total genomic DNA meth-

ylation using standard techniques or a cotransfected in vitro methylated plasmid using a HpaII /MspI restriction enzyme analysis. Cellular transformation is measured by a soft agar assay.

5

#### Demethylation of pBluescript SK(+) Plasmid

About 4  $\mu$ g plasmid pBluescript SK (Stratagene) was subjected to methylation using SssI methylase. The methylated plasmid (4 ng) was incubated for different time points as indicated with 30  $\mu$ l of DNA dMTase Fraction 4 of DEAE-Sephacel™ column under standard conditions, extracted with phenol: chloroform and precipitated with ethanol. About 1 ng of the plasmid were subjected to digestion with 10 units each of either of the restriction endonuclease EcoRII (GIBCO-BRL), DpnI, or HpaII (New England Biolabs) before and after methylation as well as after DNA dMTase treatment in a reaction volume of 10  $\mu$ l for 2 hour at 37°C. Following restriction digestion the plasmids were extracted with phenol:chloroform, ethanol precipitated and resuspended in 10  $\mu$ l. The plasmids were electrophoresed on a 0.8% (w/w) Agarose gel, transferred onto a Hybond™ Nylon membrane and hybridized with pBluescript SK(+) plasmid which was <sup>32</sup>P labeled by random-priming (Boehringer Mannheim).

dMTase activity coelutes with a ~45 KDa polypeptide when sized under denaturing conditions but migrates as a higher molecular weight complex under non denaturing conditions. dMTase was purified up to 500,000 fold by four chromatographic steps (Table 1). We first determined the identity of the polypeptide associated with dMTase activity by SDS-PAGE analysis of the active fractions. As observed in Fig. 7a, a cluster of 4 polypeptide bands from ~44 KDa to 35 KDa coelute with dMTase activity in the last two chromatographic steps

(the lower fragment might be a degradation product as evidenced by its abundance in the later chromatographic steps). However when the active DEAE-Sephacel fraction is size fractionated on a 4% non denaturing acrylamide column, the dMTase activity elutes at the high molecular weight of ~170 KDa (Fig. 7c, fraction 63). SDS-PAGE analysis of this fraction (63) reveals only two bands (Fig. 7b) observed in the active chromatographic fractions (Fig. 7a). To further determine whether dMTase is found in a multimeric complex, fraction 63 was size fractionated on a glycerol gradient (Fig. 7d) and DNA dMTase activity eluted at the ~170 kDa range. As only two main small polypeptides were identified in fraction 63 (approximately 35-43 KDa), dMTase is probably found in either a homomeric complex if only one of the two peptides is dMTase or a heteromeric complex if both polypeptides are associated with dMTase activity.

**a. Identification of a lead DNA dMTase candidate by  
homology search of dbEST**

As the purification of dMTase suggests that the dMTase is of very low abundance, only ~19 ng of dMTase could be isolated from 6 mg of nuclear extract (Table 1), we opted for cloning the dMTase based on its following functional properties. First, since dMTase specifically demethylates methylated CG dinucleotides, we assumed that it should bear the ability to recognize methylated CG dinucleotides. Second, the demethylase transforms methylated cytosine in DNA to cytosine. Third, the demethylase releases the methyl group as a volatile compound.

Previous reports have shown that proteins interacting with methylated DNA share a common domain (MDBD). A TBLASTN search of the dbEST database identified a novel expression tag cDNA (from a T-cell lymphoma Homo sapiens cDNA 5' end) (gb/AA361957/AA361957

EST71295) and the mouse homologue ((gb/W97165/W97165  
mf90g05.r1) from Soares mouse embryo NbME13.5) with  
unknown function that bears homology to the MDBD  
(Fig. 8a). A search of the GenBank database verified  
5 that it is a novel cDNA that has not been included in  
GenBank. Alignment of the novel EST and MeCP2 and  
MeCP1 associated protein has revealed no homology  
beyond the previously characterized MDBD which is con-  
sistent with a different function for this methylated  
10 DNA binding protein. A 201bp fragment bearing the  
sequence identified in the search was reverse tran-  
scribed and amplified from human lung cancer cell line  
A549 RNA and was used to screen a cDNA library from  
Hela cells. The largest insert cloned was of 1.36 kb  
15 size and its sequence identity with the EST sequence  
was determined. The cDNA is novel and has no homologue  
in GenBank and no function has ever been assigned to  
it. A virtual translation of the protein identified an  
open reading frame (ORF) of 262 amino acids (Fig. 8b).  
20 The ORF may extend further 5' as no in frame stop codon  
was found upstream of this ATG. However, RACE analy-  
ses and further searches of the dbEST have failed to  
identify 5' sequences upstream to the one identified in  
our screening.

25 A BLAST search of the candidate protein using  
the Predict protein server against a database of pro-  
tein domain families has identified only the MDBD  
domain and found no homologue to the sequence in the  
data base search. No other functional motifs were  
30 identified by the Prosite analysis. This is consistent  
with a novel biochemical function for this protein. A  
coiled coil prediction of the sequence identified a  
coiled coil domain which is known to play a role in  
protein protein interactions.

The identified cDNA encodes an mRNA that is widely expressed in human cells as revealed by a Northern blot analysis of human poly A+ mRNA (Fig. 8c) as one major transcript of ~ 1.6 kb which is close to the size of the cloned cDNA, verifying that the cloned cDNA does not represent a highly repetitive RNA but rather a mRNA encoded by a single or low copy number gene.

#### 10 In vitro translated candidate cDNA bears dMTase activity

A conclusive proof for the existence of a single protein that *bona fide* demethylates DNA is to demonstrate that an *in vitro* translated candidate cDNA can volatilize methyl groups from methylated DNA and transform a methyl cytosine to cytosine in an isolated system. The candidate dMTase cDNA was subcloned it into a pcDNA3.1/His Xpress (INVITROGEN) expression vector in the putative translation frame (pcDNA3.1His A) and in a single base frame shift (pcDNA3.1His B), and was *in vitro* transcribed and translated in the presence of <sup>35</sup>S-methionine and the resulting translation products were resolved by SDS-PAGE. Autoradiography revealed a ~40KDa protein (Fig. 10a). The apparent size of the *in vitro* translated protein is shorter by ~3-5 KDa from the apparent size of the purified protein. The cloned cDNA might be missing some upstream amino acids as discussed above or might be differently modified in human cells.

Two tests established whether the *in vitro* translated candidate cDNA is a *bona fide* dMTase. We first tested whether *in vitro* translated protein (purified on a Ni<sup>2+</sup> charged agarose resin) can volatilize and release methyl residues in [<sup>3</sup>H]-CH<sub>3</sub>-DNA using a radioactive trapping volatilization assay. To verify that the volatilized counts are true <sup>3</sup>H counts, a spectrum analysis was performed. As demonstrated in Fig.

10b no volatilization of tritiated methyl residues is observed in the misframe dMTase (misframe) whereas in vitro translated putative dMTase cDNA catalyzes the volatilization of  $^3\text{H}-\text{CH}_3$  residues which are trapped in the scintillation cocktail.

Second, *in vitro* translated dMTase cDNA transforms  $\text{CH}_3$ -cytosine residing in  $[\text{P}^{32}]\text{-}\alpha\text{-dGTP}$  labeled plasmid DNA or in [methyl-dC32pdG]<sub>n</sub> double stranded oligomer DNA to cytosine, whereas a frame shift in vitro translated dMTase does not demethylate DNA (Fig. 10d). This demonstrates that the dMTase activity is dependent on the dMTase translation product and not a contaminating activity found in the *in vitro* translation kit that copurifies with the putative dMTase. The reaction carried out by the *in vitro* translated dMTase displays: dependence on the dose of *in vitro* translated product (Fig. 10c), time dependence (Fig. 10d) and dependence on translated protein (Fig. 10b & d misframe, Fig. 10c protease K treatment). Taken together, these results strongly suggest that the cDNA cloned here codes for a *bona fide* enzymatic DNA demethylase activity.

#### Transiently transfected dMTase cDNA demethylates DNA

dMTase cDNA and the pcDNA3.1HisC vector control were transiently transfected into human embryonal kidney cells to test whether the cDNA can direct expression of dMTase activity in human cells. The His-tagged proteins were bound to  $\text{Ni}^{2+}$  agarose resin and eluted from the resin with increasing concentrations of imidazole. The expression of the transfected dMTase was verified by a Western blot analysis (Fig. 11b). The imidazole fractions were assayed for their ability to volatilize and release methyl residues in  $[\text{H}^3]\text{-CH}_3\text{-DNA}$  using a radioactive trapping volatilization assay 1. As observed in Fig. 11a, imidazole fractions from

dmTase transfected cells volatilize [ $^3\text{H}$ ]- $\text{CH}_3$ , whereas no tritiated counts are detected in DNA treated with imidazole fractions from cells transfected with a misframe mutation of dmTase or non transfected cells. The transiently expressed dmTase transforms methylated cytosine in DNA to cytosine residing in two different substrates (Figs. 11c & 11d), in a protein dependent manner (Figs. 11c & 11e), and the reaction displays substrate dependence and saturability (Fig. 11f). Transiently expressed dmTase was loaded on a non denaturing glycerol gradient to determine its native MW. Similar to dmTase purified from human cells, cloned and purified dmTase activity fractionated at the 160-190 KDa range (data not shown). This is consistent with self association of cloned dmTase possibly mediated by the coiled-coil domain.

**Cloned DNA dmTase catalyzes a hydrolysis of 5-methylcytosine to release methanol**

We determined the mechanism by which methyl residues are released by the cloned dmTase (from Fig. 11) and compared it to the purified *bona fide* dmTase activity. Increasing amounts of non labeled [methyl-dCpdG] DNA were incubated with either the *bona fide* dmTase activity purified from A549 cells or the cloned dmTase in the presence of [ $^3\text{H}$ ] water for 3 hours followed by digestion to mononucleotides, a thin layer chromatography and autoradiography. As Fig. 12a shows, both reactions replace the methyl group in 5-methylcytosine with a proton donated from water as indicated by the presence of [ $^3\text{H}$ ] label in cytosine.

The identity of the leaving methyl group in the demethylation reaction catalyzed by the purified *bona fide* dmTase activity was shown to be methanol. In order to identify the form that the methyl residue leaves as in the demethylation reaction catalyzed by



the cloned dMTase an identical gas chromatography/mass spectrometry analysis of the reaction products was performed as in 1. Only the properly translated form of dMTase (both *in vitro* translated and transiently transfected and purified) is able to produce ions characteristic of methanol in a mass spectrometric analysis (mass of 32 and 29, Fig. 12b). These results suggest that the demethylation reaction catalyzed by the cloned dMTase is hydrolysis of the 5-methyl-cytosine to cytosine and methanol as described for the purified dMTase1.

#### **DNA dMTase activity is undetectable in nontransformed cells**

The assays for dMTase activity described here and the cloning of DNA dMTase cDNA enables a study of its expression at different cellular states. Global hypomethylation of DNA is a common observation in cancer cells. This has been a perplexing observation, since DNA MeTase activity is elevated in cancer cells. Hyperactivation of DNA MeTase has been proposed to play a role in cancer development. This paradox raises questions on the proposed role of the elevated levels of DNA MeTase in cancer cells. One simple explanation that has been previously suggested to resolve this paradox is that cancer cells express induced levels of DNA dMTase. We compared the DNA dMTase activity in equal concentrations of DEAE-Sephadex fractionated nuclear extracts (fractions 9-10) prepared from a number of carcinoma cell lines H446, Colo 205, Hela, and A549 with a similar preparation from human skin fibroblast cells at initial rate conditions using [mdC32pdG]n double stranded oligomer as a substrate. As observed in Fig. 13a, whereas DNA dMTase activity is readily observed in all carcinoma cell lines, it is undetectable in nontransformed human cells. The absence of dMTase activity in human primary cells

reflects the situation *in vivo* since dMTase activity is undetectable in preparations from different murine tissues whereas dMTase activity is present in a murine carcinoma cell line P19 that was transfected with the H-Ras protooncogene, or human tumors carried as xenografts in the same strain of mouse (Fig. 1a: COLO 205, A549. Hela). These conclusions were verified using the radioactive-trapping volatilization assay shown in Fig. 13c.

Since dMTase mRNA has been detected using a sensitive poly A+ Northern blot in all normal human tissues, we tested the hypothesis that the absence of detected dMTase activity in normal tissues reflects a quantitative difference in DNA dMTase mRNA between normal tissues and cancer lines. A Northern blot analysis and quantification of dMTase mRNA by a slot blot analysis shown in Fig. 13d using total RNA supports this hypothesis. Whereas minute levels of dMTase mRNA are detected in normal tissues, high levels of dMTase are expressed in a murine carcinoma cell line Y1 that bears a 30 fold amplification of *Ha-ras*.

**A second DNA demethylase dMTase2 identified in human and mouse**

cDNA sequences, predicted amino acid sequences, and GenBank accession numbers of both dMTase1 and dMTase2 from human and mouse are shown. We claim that the high level of identity of the two proteins (Figs 9c and e) suggests that the two proteins can perform the same function, DNA demethylation. The N-terminals of dMTase1 and dMTase2 contain a Methylated DNA Binding Domain (MBD) and near their C-terminals is a coiled-coil domain, however the middle portions of the protein sequences have no homology to any know structural or catalytic motif. Importantly, their middle regions are still extensively homologous suggesting that the cata-

lytic site of the demethylase activity lies in this area on both proteins.

**Induced expression of DNA demethylase in the Antisense orientation inhibits tumorigenesis ex vivo**

5 To test the hypothesis that inhibition of DNA dMTase can inhibit tumorigenesis tetracycline inducible vectors carrying the human dMTase1 cDNA in either the sense or antisense orientation were constructed and transiently transfected into HEK 293 cells, treated for 10 48 hours either in the presence or absence of doxycycline (a tetracycline analogue), selected for the last 24 hours with puromycin, and then plated on soft agar and allowed to grow for seven days. After seven days colonies were scored and the data presented clearly 15 show that doxycycline induced expression of the dMTase1 cDNA in the antisense orientation reduced colony formation (Fig. 15).

**Imidazole is a small molecule inhibitor of DNA demethylase activity**

20 A template small molecule, imidazole, was tested for the ability to inhibit DNA dMTase activity. In a volatilization of radioactive methyl residues assay, concentrations from 1 $\mu$ M to 10mM of imidazole were incubated in a typical volatilization of radioactive methyl 25 residues as described above. The graph clearly demonstrates a dose dependent inhibition of DNA dMTase activity by imidazole, and validates a rationale for testing imidazole based molecules as inhibitors of DNA dMTase activity (Fig. 16).

30 **Identification of DNA demethylase cDNAs and protein sequences**

**Fig. 9a** illustrates cDNA sequence of human dMTase1 (SEQ ID NO:1) and its predicted amino acid sequence (SEQ ID NO:2), including its Genbank location. **Fig. 9b** illustrates cDNA sequence of human dMTase2 (SEQ ID NO:3) and 35 its predicted amino acid sequence (SEQ ID NO:4), includ-

ing its GenBank location. **Fig. 9c** illustrates protein sequence alignment of human dMTase1 and human dMTase2. **Fig. 9d** illustrates cDNA sequence of mouse dMTase1 (SEQ ID NO:5) and its predicted amino acid sequence (SEQ ID NO:6), including its GenBank location. **Fig. 9e** illustrates cDNA sequence of mouse dMTase2 (SEQ ID NO:7) and its predicted amino acid sequence (SEQ ID NO:8), including its GenBank location. **Fig. 9f** illustrates protein sequence alignment of mouse dMTase1 and mouse dMTase2.

While the invention has been described in connection with specific embodiments thereof, it will be understood that it is capable of further modifications and this application is intended to cover any variations, uses, or adaptations of the invention following, in general, the principles of the invention and including such departures from the present disclosure as come within known or customary practice within the art to which the invention pertains and as may be applied to the essential features hereinbefore set forth, and as follows in the scope of the appended claims.

ART 34 AMDT

WHAT IS CLAIMED IS:

1. A DNA demethylase enzyme and/or homologue thereof, which comprises an amino acid sequence set forth in SEQ ID NOS:2, 4, 6 and 8 and homologue thereof, and wherein said DNA demethylase enzyme has about 40 KDa and is overexpressed in cancer cells.
2. A cDNA encoding a human demethylase of claim 1, which comprises a sequence set forth in SEQ ID NOS:1 and 3.
3. A cDNA homologous to the cDNA of claim 2, wherein said cDNA encoding mouse demethylase set forth in SEQ ID NOS:5 and 7.
4. The use of the expression of demethylase cDNA of claims 2 or 3 to alter DNA methylation patterns of DNA in vitro in cells or in vivo in humans, animals and in plants.
5. The use of claim 4, wherein said demethylase cDNA expression is under the direction of mammalian promoters.
6. The use of claim 5, wherein said promoter is CMV.
7. The use of claim 4, wherein said demethylase cDNA expression is under plant specific promoters to alter methylation in plants and to allow for altering states of development of plants and expression of foreign genes in plants.
8. The use of claim 4, wherein said demethylase cDNA expression is in the antisense orientation to inhibit demethylase in cancer cells for therapeutic processes.

005060-4745560

9. The use of claim 9, wherein expression of demethylase cDNA in mammalian cells is to alter their differentiation state and to generate stem cells for therapeutics, cells for animal cloning and to improve expression of foreign genes.

10. The use of the expression of demethylase cDNA of claims 2 or 3 in bacterial or insect cells for production of large amounts of demethylase.

11. The use of the expression of demethylase cDNA of claims 2 or 3 for the production of protein in vertebrate, insect or bacterial cells.

12. The use of claim 11 for producing antibodies against demethylase.

13. The use of the sequence of demethylase cDNA of claim 2 as a template to design antisense oligonucleotides and ribozymes.

14. The use of the predicted peptide sequence of demethylase cDNA of claim 2 to produce polyclonal or monoclonal antibodies against demethylase.

15. The use of expression of cDNA of claim 2 or 3 in two hybrid systems in yeast to identify proteins interacting with demethylase for diagnostic and therapeutic purposes.

16. The use of expression of cDNA of claim 2 or 3 in bacterial, vertebrate or insect cells to produce large amounts of demethylase for high throughput screening of

005060-443300

demethylase inhibitors for therapeutics and biotechnology and for obtaining the x-ray crystal structure.

17. A volatile assay for high throughput screening of demethylase inhibitors as therapeutics and anticancer agents which comprises the steps of:

- a) using transcribed and translated demethylase cDNA of claim 2 or 3 *in vitro* to convert methylcytosine present in methylated DNA samples to cytosine present in DNA and volatilize methyl group;
- b) determining the absence or minute amount of volatilize methyl group as an indication of an active demethylase inhibitor.


18. A volatile assay for the diagnostics of cancer in a patient sample which comprises the steps of:

- a) determining demethylase activity in patient samples by determining conversion of methylcytosine present in methylated DNA to cytosine present in DNA and volatilization of the methyl group released as methanol;
- b) determining the presence or minute amount of volatilized methyl group as an indication of cancer in said patient sample.

19. Use of an antagonist or inhibitor of DNA demethylase of claim 1 or 2 for the manufacture of a medication for cancer treatment, for restoring an aberrant methylation pattern in a patient DNA, or for changing a methylation pattern in a patient DNA.

20. Use according to claim 19, wherein said antagonist is a double stranded oligonucleotide that inhibits demethylase at a  $K_i$  of 50nM.

21. Use according to claim 20, wherein said oligonucleotide is



22. Use according to claim 19, wherein the inhibitor comprises an anti-DNA demethylase antibody or an antisense oligonucleotide of DNA demethylase or a small molecule.

23. Use according to one of claims 19 or 22, wherein the change of the methylation pattern activates a silent gene.

24. Use according to claim 23, wherein the activation of a silent gene permits the correction of genetic defect.

25. Use according to claim 24, wherein said genetic defect is  $\beta$ -thalassemia or sickle cell anemia.

26. Use of the demethylase of claim 1, for removing methyl groups on DNA *in vitro*.

27. Use of the demethylase of claim 1 or its cDNA of claim 2, for changing the state of differentiation of a cell to allow gene therapy, stem cell selection or cell cloning.

28. Use of the demethylase of claim 1 or its cDNA, of claim 2 for inhibiting methylation in cancer cells using vector mediated gene therapy.

29. An assay for the diagnostic of cancer in a patient, which comprises determining the level of expression of DNA demethylase of claim 1 in a sample



from said patient, wherein overexpression of said DNA demethylase is indicative of cancer cells.

005000 444444

1/50












FIG. 1A




11

EVIDENCE SHEET (DII E 25)




First






72. Five

5/50

009000.tif 2500



6/50



Labeled nucleotide:  
[ $\alpha$ 32P]-dGTP


Labeled nucleotide:  
[ $\alpha$ 32P]-dCTP








8/50








9/50




4E

09/554414.000600

10/50


FIG. 4F



$$\Delta G_{\text{Reaction}} = (93) - (103 + 91.5) = (-101.5) \text{ Kcal}$$


Fig. 5

12/50




— — — — — BA

13/50




14/50



— mdCMP  
 — dCMP

HM Control  
 -RNase  
 +RNase



— mdCMP  
 — dCMP

— mdCMP  
 — dCMP





16/50




Figure 7C


Figure 7D

FEED - BA

\_\_\_\_\_

18/50

005000-1111350



# Human DNA demethylase cDNA-dMTase1 and predicted amino acid sequence

5' gggggcgctg cccgagaag gcggagacaa gatggccgcc catagcgctt ggaggaccta  
 agaggcggtg gccggggcca cggccgggc aggagggccg ctctgtgcgc gcccgctcta  
 tgatgcttgc gcgcgtccc gcgcgcgc gcctcgggcg ggcgggtctt cgggattcc  
 aagggtcgg ttacggaaga agcgcagcg cgctggga gggggtgga tgcgcgcgca  
 cccgggggga ggcgctgct gccggagca ggaggaggg gagagtgcgg cgggcggcag  
 cggcgtggc ggcgactccg ccatagagca ggggggccag ggcgcgcgc tgcgccgctc  
 cccggtgagc ggcgtgcga ggaaggcg tcggggcgcc gccgtggc gggggcggtg  
 gaagcaggcg ggcggggcg gcgctctg tggcgtggc cggggccggg gccgtggccg  
 gggacgggga cggggccggg gccggggcg gcgagtgcc cgcagcggcct  
 tggcggcgac ggcggcggt gcggcgcg gcgcagcgg ggccggcg ccccgggcg  
 ggagccggtc ccttccgt cggggagcg gggccggg ccaggggac cccggggccac  
 ggagagcggg aagaggatgg attgccggc cctccccc ggatggaaga aggaggaagt  
 gatccgaaa tctgggctaa gtgctggcaa ggcgatgtc tactactca gtccaagtgg  
 taagaagtcc agaagcaagc ctcagttggc aaggtacctg ggaatactg ttgatctcag  
 cagttttgac ttcagaactg gaaagatgat gcctagtaaa ttacagaaga acaacagag  
 actgcgaaac gatcctctca atcaaaataa gggtaaacca gacttgaata caacattgcc  
 aattagacaa acagcatcaa ttttcaaca accggtaacc aaagtcacaa atcatcctag

19/50

FIG. 1

20/50

taataaagtg aaatcagacc cacaacgaat gaatgaacag ccacgtcagc ttttctggga  
gaagaggcta caaggactta gtgcatacaga tgtaacagaa caaattataa aaaccatgga  
actaccctaaa ggtcttcaag gagttggtcc aggtagcaat gatgagaccc ttttatctgc  
tgttgccagt gctttgcaca caagctctgc gccaatcaca gggcaagtct ccgctgctgt  
ggaaaagaac cctgctgtt ggcttaacac atctcaacc ctctgcaaa cttttattgt  
cacagatgaa gacatcagga aacaggaaga gcgagtacag caagtacgca agaaattgga  
agaagcactg atggcagaca tcttgtcgcg agctgctgat acagaagaga tggatatgga  
aatggacagt ggagatgaag cctaagaata tgatcaggta actttcgacc gactttcccc  
aagrgaaaat tcctagaaat tgaacaaaaa tgttccact ggcttttgcc tgtaagaaaa  
aaaatgtacc cgagcacata gagcttttta atagcactaa ccaatgcctt ttagatgta  
tttttgatgt atatatctat tattcaaaaa atcatgttta ttttgagtcc taggacttaa  
aattagtctt ttgtaatatc aagcaggacc ctaagatgaa gctgagcttt tgatgccagg  
tgcaatctac tggaaatgta gcacttacgt aaaacattg tttccccac agttttaata  
agaacagatc aggaattcta aataaaattc ccagttaaa attattgtga cttcactgta  
tataaacata tttttatact ttattgaaag gggacacctg tacattcttc catcatcact  
gtaagacaa ataaatgatt atattcaca aaaaaaaaaa 3'

SEQ ID NO:1

FIG - 9B

21/50

MRAHPGGGCCPEEGESAAAGSGAGGDSAIEQGGQGSALAPSPVSGVR  
 REGARGGGRGRWKQAGRGGVCGRGRGRGRGRGRGRGRGRPPSG  
 GSGLGDDGGCGGGGAPRRFPVFPSPGSAGPGPRGPRATESGKRM  
 DCPALPPGWKKEEVIRKSGLSAGKSDVYFSPSGKKFRSKPQLARYLGNT  
 VDLSSFDFTGKMMPSKLQKNKQRLRNDPLNQNKGKPDNLNLTPIRQTAS  
 IFKQPVTKVTHNPSNVKSDPQRMNEQPRQLFWEKRLQGLSASDVTEQII  
 KTMELPKGLQGVGPGSNDETLLSAVASALHTSSAPITGQVSAAVEKNPAV  
 WLNTSQPLCKAFIVTDEDIRKQEEERVQQVRKKLEELMADILSRAADTEE  
 MDIEMDSGDEA

SEQ ID NO:2

FIG. 1

# Human DNA demethylase homologue-dMTase2 and predicted amino acid sequence

22/50

5' agcgggccga ggagccgggc gcaatggagc ggaagaggtg ggagtcccgc gcgctcccgc  
 agggctggga gaggaagaa gtgccagaa ggtcgggggt gtgcggccggc cacagggatg  
 tcttttacta tagcccgagc gggaagaagt tccgcagcaa gccgcagctg gcgcgctacc  
 tgggcggctc catggacctg agcaccttcg acttccgcac gggcaagatg ctgatgagca  
 agatgaacaa gagccgccag cgcgtgcgct acgactcctc caaccaggtc aagggaagc  
 ccgacctgaa cacggcgctg cccgtgcgcc agacggcgct catcttcaag cagccggtga  
 ccaagattac caaccacccc agcaacaagg tcaagagcga cccgcagaag gcggtggacc  
 agccgcgcca gctcttctgg gagaagaagc tgagcggcct gaacgccttc gacattgctg  
 aggagctggt caagacctg gacctccca agggcctgca gggggtggga cctggctgca  
 cggatgagac gctgctgtcg gccatcgcca gcgccctgca cactagcacc atgcccatca  
 cgggacagct ctcgccgccc gtggagaaga acccggcgt atggctcaac accacgcagc  
 ccctgtgcaa agccttcatt gtgaccgacg aggacatcag gaagcaggaa gagctggtgc  
 agcagggtgcg gaagcggctg gaggagggcg tgatggcga catgctggcg cacgtggagg  
 agctggcccg tgacggggag gcgcgctgg acaaggcctg cgtgaggac gacgacgagg  
 aagacgagga ggaggaggag gaggagccc acccggacc ggagatggag cacgtctagg  
 gcagaggccc tgccgagagc ccgtgctgcc tgctggagcc gcctgcagac gcggtcctcg  
 gcccacagt aaccaggctc ggcggcgaag ccagccttg gagacacca ggaggaaggc  
 cgtgctcctg gctccctcct cggcccgctc cacttccc ggccctcggg gcacacagct  
 ggggctgccc ccacccgaaa gaccctccac gctcgtcctc tacagagtcc ggcttcggga  
 agtgcggggt gctcctgggc cctgcctggc tcctacgac ctttgggctc gaggccagct

715-90

23/50

cctccccatg cccgctgtcc cagctccttg agactggaga gcagccagca ggtgcccggc  
agctcggcgc cacggcttgc tgacagctgg gaggtttctt cggctctggag gcgtagtttt  
gaaactcaca tcaccactg tgcagcgtga ggacgggact ctggtctgct gtgggggggca  
tgcaggacgg cgccactctc tgccctgcca tgcggctggt ggtgccacag agcctcacgg  
tgccctgagt gctgcccag ggaggccgct ctcttcagt aatgtaaca cagtcgaggc  
acgtcatcgg gcagccttcc ctgtgtgcca acgccagcct tcgcttctga aaaccaaact  
ccagccgctg ccagtcggga cttggtcgc cggcgctgcc agaattgctcc actgccagcc  
ggccccctg cctcggtttc ccttctgttt agtggcgaca caggcaccca gcttgggggt  
ggtgctgacg ctcccagggt tcccaggagc cactgggaca ggtgaggct ccagacgct  
cctcgagggt ccagctctc caggagctt ctggcccaag gcgttcttga gggatctgct  
ccttaacccc ccagtgcctt ggcgagggca ggttccaagc cacagacgcc tgcgccgagt  
ggacttttgcg gccagtccct ggtgacctc ctgggccctg cttggcccagt gaggttctct  
aacgggtggg ttcawtggcc tggcccvagc gagccccac ctgcattgac cttagggcca  
tagagagggc ctgtcccggg gctgcccag ccaaggatct ggtcgtgcc ccagggggac  
tgatgggcaa gagtgcgcc tgtggctgga ctgtgaccat ccctgatggg gcctgaccgc  
gggagctgag gaagcgccgc tcaccgtct gccctccaag gaccgcatg gaggcagtgg  
gctggcagct tcctgctgct ccctgtcaga gtcaaaagcac aaatcctcag gacgggctca  
agggccaggg cagccgaggg aagctccagg tggggaccac gtctcctga ggttggtgcc  
cactggctgg gaccctttgc agtggggtgg cctccccctt gtctgcctgg tggagggagc  
cgtgggctg gggacgtgac tgaataaagc caccatgggt ggatgtgctt gg 3'

SEQ ID NO: 3

FIG. 1



24/50

MERKRWECPALPQGWEREVPRRSGLSAGHRDVFYSPSGKKFRSKPQLA  
RYLGGSMDLSTFDERTGKMLMSKMNKSQRVRDYDSSNQVKGPDLNTALP  
VRQTA S I F K Q P V T K I T N H P S N K V K S D P Q K A V D Q P R Q L F W E K K L S G L N A F D  
I A E E L V K T M D L P K G L Q G V G P G C T D E T L L S A I A S A L H T S T M P I T G Q L S A A V  
E K N P G V W L N T T Q P L C K A F M V T D E D I R K Q E E L V Q Q V R K R L E E A L M A D M L A H  
V E E L A R D G E A P L D K A C A E D D D E E D E E E E E P D P D P E M E H V

SEQ ID NO: 4

TFE - BF

Lipman-Pearson Protein Alignment

Kluple: 2; Gap Penalty: 4; Gap Length Penalty: 12

Seq1(1>411)	Seq2(1>291)	Similarity	Gap	Gap	Consensus
human dMTase1 protein	human dMTase2 protein	Index	Number	Length	Length
(148>397)	(4>253)	76.0	0	0	250
(148>397)	(4>253)	76.0	0	0	250
v150	v170	v180	v200	v210	
KRMDCPALPPGWKKEEVIRKSGLSAGKSDVYFSPSGKKFRSKPQLARYLGNIVDLSSFDFRTIGKMMPK					
KR :CPALP.GW.:EEV R:SGLSAG..DV:Y:SPSGKKFRSKPQLARYLG.:DLS:FDFTIGKM:SK					
KRWECPALPQGWEREVEVPRRSGLSAGHRDVFYSPSGKKFRSKPQLARYLGSGMDLSITDFRTIGKMLMSK					
^10	^20	^30	^40	^50	^60
^70					
					25/50
v220	v230	v240	v250	v260	v270
					v280
LQKNKQRLRNDPLNQNKGKPDNLNITLPIRQTASIFKQPVTKVINHPSNKKVKSDFQRMNEQPRQLFWEKRL					
::K::QR:R D: NQ KGKPDINT:LP:RQTASIFKQPVTK:TNHPSNKKVKSDFQ: :QPRQLFWEK:L					
MNKSQRVRYDSSNQVGKPDNLNTALPVRQTASIFKQPVTKITNHPSNKKVKSDFQKAVDQPRQLFWEKKL					
^80	^90	^100	^110	^120	^130
					^140
					<u>7366</u> - 96

v290 v300 v310 v320 v330 v340 v350  
QGLSASDVTEQIIKIMELPKGLQGVGPGSNDETLLSAVASALHTSSAPTITGQVSAAVEKNPAMWLNTSQP  
GL:A D::E:::KIM:L PKGLQGVGPG..DETLLSA:ASALHTS: PITGQ:SAAVEKNP:VWLNT:QP  
SGLNAFDIAEELVKIMDLPKGLQGVGPGCTDETLLSAIASALHTSIMPITGQLSAAVEKNPFGWLNTIQP  
^150 ^160 ^170 ^180 ^190 ^200 ^210

26/50

v360 v370 v380 v390  
LCKAFIVIDEEDIRKQEEERVQQVRKKLFEALMADILSRAAD  
LCKAF:VIDEEDIRKQEE VQQVRK:LEEFALMAD:L:::  
LCKAFMVIDEEDIRKQEEELVQQVRKRLFEALMADMLAHVEE  
^220 ^230 ^240 ^250

FEEL - BH

# Mouse DNA demethylase-dMTase1 and predicted amino acid sequence

5' ccgctctgcg ggcggggcggt gtctccggga ttccaaagggc tcggttacgg aagaagcgca  
gagccggctg gggagggggc tggatgcgcg cgcaccggg gggagggcgc tgctgcccg  
agcaggagga ggggagagc gcggcgggcg gcagcggcg tcggcgcgac tccgccatag  
agcagggggg ccagggcagc gcgctcgctc cgtccccgt gagcggcgtg cgcaggggaag  
gcgctcgggg cggcgccgtt ggcggggggc ggtggaagca ggcggccccg ggcggcgggc  
tctgtggcgg tggccgtggc cgtggccggg gtcggggcgg tgccggggc cggggccggg  
gccgcggcgg tcccagagt ggcggcagcg gccttggcgg gcacggcggc ggcggcgcg  
gcggctgcgg cgtcggcagc ggtggcgcg tcgcccccg gcgggatacct gtccctttcc  
cgtcggggag ctcgggggc ctcggggcgg gggccaggg gacccgggc caggagagc gggaaagga  
tgactgccc ggccctccc caagagcgat gtctactact ccgcatgga agaaggagga agtatccga aaatcagggc  
tcagtgcctg gcaagcgat gcaggaaatg ctgttgacct tcagtaagaag tggtaagta ttcagaagta  
aacctcagct ggcaagatag gatgcctagt aaattacaga agaacaagca gagactcgg aatgaccccc  
ccggcaagat gatgcctagt caagggtaaa ccagacctga acacaacatt gccaataga caaactgcat  
tcaatcagaa caagggtgta gcaaccagta accaaattca cgaaccaccc gagcaataag gtgaagtcag  
acccccagcg gatgaatgaa caaccagtc agcttttctg agagaagagg ctacaaggac  
ttagcgcac agatgtaaca gaacaatta taaaaccat ggagctacct aaaggtcttc  
aaggagtcgg tccaggtagc aatgacgaga cccttctgtc tgctgtggcc agtgctttac

27/50

FIG. 1

28/50

acacaagctc tgcgcccatc acaggacaag tctctgctgc cgtggaaaag aacctgctg  
tttggcttaa cacatctcaa cccctctgca aagctttcat tgttacagat gaagacatta  
ggaaacagga agagcgagtc caacaagtac gcaagaaact ggaggaggca ctgatggccg  
acatcctgtc ccgggctgcg gacacggagg aagtagacat tgacatggac agtggagatg  
aggcgtiaga atatgattcag gtaactttcg actgaccttc cccaagagca aattgctaga  
aacagaatta aacattttcc actgggtttc gcctgtaaga aaaagtgtac ctgagcacat  
agctttttaa tagcactaac caatgccttt ttagatgtat ttttgatgta tatactctatt  
attccaaatg atgtttattt tgaatcctag gacttaaaat gactcttta taatagcaag  
cagggccctt ccggtgcagt gcagctttga ggccagggtgc agtctactgg aaaggtagca  
cttacgtgaa atatttgttt cccccacagt tttaataataa acagatcagg agtaccaaat  
aagtttccca attaaagatt attatacttc actgtatata aacagatttt tatactttat  
tgaaagaaga tacctgtaca ttcttccatc atcactgtaa agacaaataa atgactatat  
tcac 3'

SEQ ID NO:5

7-15-91

MRAHPGGGRCCPEQEEGESAAGSGAGGDSAIEQGQGSALAPSPVSGVR  
REGARGGGRGRWKQAAARGGVCGRGRGRGRGRGRGRGRGRGRPPQSG  
GSGLGGDGGGAGGCGVSGGVA PRRDVPFPSSGPGPRGRATESG  
KRMDCPALPPGWKKEEVIRKSGLSAGKSDVYFSPSGKKFRSKPQLARYL  
GNAVDLSSFDFTGKMMPSKLQKNKQRLRNDPLNQNGKPDLTTLPIRQ  
TASIFKQPVTKFTNHPSNKVKSDPQRMNEQPRQLFWEKRLQGLSASDVTE  
QIIKTMELPKGLQGVGPGSNDETLLSAVASALHTSSAPITGQVSAAVEKN  
PAVWLNTSQPLCKAFIVTDEDIRKQEEERVQQVRKKLEALMADILSRAAD  
TEEVDDIMDSGDEA

SEQ ID NO:6

715-9K

# Mouse DNA demethylase-dMTase2 and predicted amino acid sequence

5' cacgcgcggg cgggtgggcg gagcgcccc ctagcgggg gctgtgaagc gcggggagggg  
 ggccgagcgg gtggcgaagc cggcgcgcg cgggctgggg gcggagggcg gagcccgctg  
 ggacagaaca gctgcggcga gtggcgcgcg gggcgcgcg gcgaatcggc acgagcccg  
 ggtcgcaac ttgcagaagc ggcggcgcg gggcatcgg ccacggcggg cggaaaaagcc  
 gggcgcaat ggagcgaag aggtgggagt gccggcgct ccgcagggc tgggaaaagg  
 aagaagtgc caggaggtcg gggctgtcgg cgggccacag ggtgtcttt tactatagcc  
 ccagcgggaa gaagtccgc agcaagccac aactggcacg ttacctgggc ggatccatgg  
 acctcagcac cttcgactc cgcaccggaa agatgttgat gaacaagatg aataagagtc  
 gccagcgtgt gcgctatgat tctccaacc aggtcaaggg caagcctgac ctgaacacccg  
 cgctgcctgt acggcagact gcattccatct tcaagcaacc ggtgaccaag atcaccaacc  
 acccagcaa caaggtcaag agcagcccg agaaggcagt ggaccagcg aggcagcttt  
 tctgggagaa gaagctaagt ggattgagt cctttgacat tgcagaagaa ctggtcagga  
 ccattggactt gcccaaggc ctgcaggag tgggccctgg ctgtacagat gagacgctgc  
 tgtcagccat tgcgagtgt ctacacca gcaccctgcc cattacaggc cagctctctg  
 cagccgtgga gaagaaccct ggtgtgtggc tgaacactgc acagccactg tgcaaaagcct  
 tcatggtgac agatgacgac atcaggaaagc aggaggagct ggtacagcag gtacggaagc  
 gcctggagga ggcactgatg gccgacatgc tagctcatgt ggaggagctt gcccgagacg  
 gggaggcacc actggacaag gcctgtgcag aggaggaaagg gagggaggag

FIG. 1

30/50

31/50

aagagccgga gccagagcga gtgtagcaca ggtgccctgc ccaagtctgg gctgcagact  
gccttcagcc ttgacctggac caggtagggg ccagacctgt aggaggcagc cgtccacctc  
ctttccaaag cctcctgctt ccaggtctca gtgcaggagg cccctgtgga ccttgaactc  
acttgtccct gcgctgcctg gcaggaagcc ccacactgaa agcagatgag cagtgaacca  
actgagaggg cacctggaca cagtcacctc cctgcctcct tatcatagga caaggccttg  
cttggcaccc aggagctggg agccgtgttg ggtgctggag gaagtctctg gaaacacacc  
tggctatgcc caccttatgt ccctaaggct attacaggcc agggttttgga ctgctccggc  
ccacagggct gccagcctc gccacactga ggtcagcag cccaccagga agtcactttc  
cttcaataaa ctgatggtag gaactgtg 3'

SEQ ID NO: 7

FIG. 1 - 9M



003000-444330

32/50

MERKRWECPALPQGWEREVPRRSGLSAGHRDVFYSPSGKKFRSKPQLA  
RYLGGSMDLSTFDFRTGKMLMNKMKSRQVRDYDSSNQVKGKPDNLNLTALP  
VRQTASIFKQPVTKI TNHPSNVKSDPQKAVDQPRQLFWEKKLSGLSAFD  
IAEELVRTMDLPKGLQGVGPGCTDETLLSAIALHTSTLPITGQLSAAV  
EKNPGVWLNTAQPLCKAFMVTDDDIRKQEELVQQVRKRLEEALMADMLAH  
VEELARDGEAPLDKACAEVEEEEEEEEEPEPERV

SEQ ID NO:8

Fig. 1 - 5N

33/50

Q

Q

Q

Q


Q

34/50

v370	v380	v390	v400
LCKAFVTD	EDIRKQEE	VQVRKLE	EALMADIL
LCKAF:VID	:DIRKQEE	VQVRK:LE	EALMAD:L
LCKAFMTD	DDIRKQEE	LVQVRKRL	EALMADML
^220	^230	^240	^250

711

35/50



misframed  
dMTase




FIG. 10A

36/50







FIG. 10B

37/50


005000-11111111



38/50


FIG. 11A

39/50






40/50

FIG. 11F

41/50



- Origin







Transient dMTase

- Origin

A549 dMTase

FIG 12A

~~FIG. 12B~~







FIGURE 13A





FIGURE 13B


44/50




137

45/50


dMTase



18s




dMTase / 18s



130

46/50

FIG. 14A






FIG. 14B






FIG. 14C




48/50




15

49/50

FIG. 16

50/50



**COMBINED DECLARATION FOR UTILITY OR DESIGN  
PATENT APPLICATION (37 CFR 1.63) AND POWER OF ATTORNEY**

I hereby claim the benefit under 35 U.S.C. 120 of any United States application(s), or 365(c) of any PCT international application designating the United States of America, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of 35 U.S.C. 112, I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56 which became available between the filing date of the prior application and the national or PCT International filing date of this application.

U.S. Parent Application or PCT Parent Number	Parent Filing Date (MM/DD/YYYY)	Parent Patent Number (if applicable)
PCT/CA98/01059	11/12/1998	

☐ Additional U.S. or PCT International application numbers are listed on a supplemental priority data sheet PTO/SB/02B attached hereto:

As a named inventor, I hereby appoint the following registered practitioner(s) to prosecute this application and to transact all business in the Patent Trademark Office connected therewith:

☐ Customer Number 
Place Customer Number Bar Code Label Here

OR ☒ Registered practitioner(s) name/registration number listed below

Name	Registration Number	Name	Registration Number
Joseph D. Evans	26,269	Herbert I. Cantor	24,392
Donald D. Evenson	26,160	Gary R. Edwards	31,824
Robert Mitchell	25,007	Guy Houle	24,971
Kevin P. Murphy	26,674	Robert Carrier	30,726
Michel J. Sofia	37,017	François Nadeau	37,570
France Côté	37,037		

Direct all correspondence to ☐ Customer Number  OR ☒ Correspondence address below

Name Joseph D. Evans  
 Address EVENSON, McKEOWN, EDWARDS & LENAHAN  
 Address Suite 700, 1200 G Street, N.W.  
 City Washington State D.C. Postal Code 20005  
 Country USA Telephone (202) 628-8800 Fax (202) 628-8844

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001 and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

**Name of sole or First Inventor:**

☐ A petition has been filed for this unsigned inventor

Given Name (first and middle [if any])

Family Name or Surname

1-00 Moshe SZYF  
 Inventor's Signature Moshe Date 28.6.2000  
 Residence: City Côte St-Luc State Québec Country Canada Citizenship Canadian  
 Post Office Address 7522 Wavell

City Côte St-Luc Province or State Québec Postal Code H4W 2L7 Country Canada

☒ Additional inventors are being named on the supplemental Additional Inventor(s) PTO/SB/02A attached hereto.

COMBINED DECLARATION FOR UTILITY OR DESIGN  
PATENT APPLICATION (37 CFR 1.63) AND POWER OF ATTORNEY

PTO/SB/02A (3-97)

**DECLARATION**

ADDITIONAL INVENTOR(S)  
Supplemental Sheet  
Page 3 of 3

**Name of Additional Joint Inventor, if any:**

☐ A petition has been filed for this unsigned inventor

Given Name (first and middle [if any])

Family Name or Surname

2-00 Sanjoy BHATTACHARYA

Inventor's Signature [Signature] Date July 6/2000

Residence: City Montréal State Québec Country Canada Citizenship Indian CAX

Post Office Address Apartment 1403

2150 Mackay Street

City Montréal Province or State Québec Postal Code Or Zip H3G 2M2 Country Canada

**Name of Additional Joint Inventor, if any:**

☐ A petition has been filed for this unsigned inventor

Given Name (first and middle [if any])

Family Name or Surname

3-00 Shyam RAMCHANDANI

Inventor's Signature [Signature] Date July 10/2000

Residence: City Niagara Falls State Ontario Country Canada Citizenship Canadian CAX

Post Office Address 5843 Hillcrest Crescent

City Niagara Falls Province or State Ontario Postal Code Or Zip L2J 2A8 Country Canada

**Name of Additional Joint Inventor, if any:**

☐ A petition has been filed for this unsigned inventor

Given Name (first and middle [if any])

Family Name or Surname

Inventor's Signature \_\_\_\_\_ Date \_\_\_\_\_

Residence: City \_\_\_\_\_ State \_\_\_\_\_ Country \_\_\_\_\_ Citizenship \_\_\_\_\_

Post Office Address \_\_\_\_\_

City \_\_\_\_\_ Province or State \_\_\_\_\_ Postal Code Or Zip \_\_\_\_\_ Country \_\_\_\_\_

☐ Additional inventors are being named on the supplemental Additional Inventor(s) PTO/SB/02A attached hereto.

## SEQUENCE LISTING

<110> MCGILL UNIVERSITY  
SZYF, Moshe  
BHATTACHARYA, Sanjoy K.  
RAMCHANDANI, Shyam

<120> DNA DEMETHYLASE, THERAPEUTIC AND  
DIAGNOSTIC USES THEREOF

<130> 1770-183"PCT" FC/ld

<150> CA 2,220,805

<151> 1997-11-12

<150> CA 2,230,991

<151> 1998-05-11

<160> 10

<170> FastSEQ for Windows Version 3.0

<210> 1

<211> 1804

<212> DNA

<213> Unknown

<400> 1

ccgctctgcg	ggcggggcgg	gtctccggga	ttccaagggc	tcggttacgg	aagaagcgca	60
gagccggctg	gggagggggc	tggatgcgcg	cgcacccggg	gggaggccgc	tgctgcccgg	120
agcaggagga	gggggagagc	gcggcgggcg	gcagcggcgc	tggcggcgac	tccgccatag	180
agcagggggg	ccagggcagc	gcgctcgctc	cgtecccggt	gagcggcggt	cgcaggggaag	240
gcgctcgggg	cggcgggcgt	ggccgggggc	ggtggaagca	ggcggcccgg	ggcggcgggc	300
tctgtggcgg	tggccgtggc	cgtggccggg	gtcggggccg	tggccggggc	cggggccggg	360
gccgcggcgg	tccccagagt	ggcggcagcg	gccttgggcg	cgacggcggc	ggcggcgcg	420
gcggctgcgg	cgtcggcagc	ggtggcgggc	tcgcccccg	gcgggatcct	gtccctttcc	480
cgctcggggg	ctcggggccg	gggcccagg	gaccccgggc	cacggagagc	gggaagagga	540
tggactgccc	ggccctcccc	cccggatgga	agaaggagga	agtgatccga	aaatcagggc	600
tcagtgcctg	caagagcgat	gtctactact	tcagtccaag	tggttaagaag	ttcagaagta	660
aacctcagct	ggcaagatac	ctgggaaatg	ctgttgacct	tagcagtttt	gacttcagga	720
ccggcaagat	gatgcctagt	aaattacaga	agaacaagca	gagactccgg	aatgaccccc	780
tcaatcagaa	caagggtaaa	ccagacctga	acacaacatt	gccaattaga	caaactgcat	840
caattttcaa	gcaaccagta	accaaattca	cgaaccaccc	gagcaataag	gtgaagtcag	900
acccccagcg	gatgaatgaa	caaccacgtc	agctttttctg	ggagaagagg	ctacaaggac	960
ttagcgcata	agatgtaaca	gaacaaatta	taaaaacccat	ggagctacct	aaagggtcttc	1020
aaggagtcgg	tccaggtagc	aatgacgaga	cccttctgtc	tgctgtggcc	agtgtctttac	1080
acacaagctc	tgcgcccata	acaggacaag	tctctgctgc	cgtggaaaag	aaccctgctg	1140
tttggttaaa	cacatctcaa	ccctctgca	aagctttcat	tgttacagat	gaagacatta	1200
ggaacacagga	agagcgagtc	caacaagtac	gcaagaaact	ggaggaggca	ctgatggccg	1260
acatcctgtc	ccgggctgcg	gacacggagg	aagtagacat	tgacatggac	agtggagatg	1320
aggcgtaaga	atatgatcag	gtaactttcg	actgaccttc	cccaagagca	aattgctaga	1380
aacagaatta	aaacatttcc	actgggtttc	gcctgtaaga	aaaagtgtac	ctgagcacat	1440
agcttttttaa	tagcactaac	caatgccttt	ttagatgtat	ttttgatgta	tatatctatt	1500
attccaaatg	atgtttatgt	tgaatcctag	gacttaaaat	gagtctttta	taatagcaag	1560
cagggccctt	ccggtgcagt	gcagctttga	ggccaggtgc	agtctactgg	aaaggtagca	1620
cttacgtgaa	atatttggtt	ccccacagt	tttaataata	acagatcagg	agtaccaaata	1680

005000-47773360

```

aagtttccca attaaagatt attatacttc actgtatata aacagatttt tatactttat 1740
tgaagaaga tacctgtaca ttcttccatc atcactgtaa agacaaataa atgactatat 1800
tcac 1804

```

```

<210> 2
<211> 411
<212> PRT
<213> Unknown

```

```

<400> 2

```

```

Met Arg Ala His Pro Gly Gly Gly Arg Cys Cys Pro Glu Gln Glu Glu
1      5      10      15
Gly Glu Ser Ala Ala Gly Gly Ser Gly Ala Gly Gly Asp Ser Ala Ile
20      25      30
Glu Gln Gly Gly Gln Gly Ser Ala Leu Ala Pro Ser Pro Val Ser Gly
35      40      45
Val Arg Arg Glu Gly Ala Arg Gly Gly Gly Arg Gly Arg Gly Arg Trp
50      55      60
Lys Gln Ala Gly Arg Gly Gly Val Cys Gly Arg Gly Arg Gly Arg
65      70      75      80
Gly Arg Gly Arg Gly Arg Gly Arg Gly Arg Gly Arg Gly Arg Gly Arg
85      90      95
Pro Pro Ser Gly Gly Ser Gly Leu Gly Gly Asp Gly Gly Gly Cys Gly
100     105     110
Gly Gly Gly Ser Gly Gly Gly Gly Ala Pro Arg Arg Glu Pro Val Pro
115     120     125
Phe Pro Ser Gly Ser Ala Gly Pro Gly Pro Arg Gly Pro Arg Ala Thr
130     135     140
Glu Ser Gly Lys Arg Met Asp Cys Pro Ala Leu Pro Pro Gly Trp Lys
145     150     155     160
Lys Glu Glu Val Ile Arg Lys Ser Gly Leu Ser Ala Gly Lys Ser Asp
165     170     175
Val Tyr Tyr Phe Ser Pro Ser Gly Lys Lys Phe Arg Ser Lys Pro Gln
180     185     190
Leu Ala Arg Tyr Leu Gly Asn Thr Val Asp Leu Ser Ser Phe Asp Phe
195     200     205
Arg Thr Gly Lys Met Met Pro Ser Lys Leu Gln Lys Asn Lys Gln Arg
210     215     220
Leu Arg Asn Asp Pro Leu Asn Gln Asn Lys Gly Lys Pro Asp Leu Asn
225     230     235     240
Thr Thr Leu Pro Ile Arg Gln Thr Ala Ser Ile Phe Lys Gln Pro Val
245     250     255
Thr Lys Val Thr Asn His Pro Ser Asn Lys Val Lys Ser Asp Pro Gln
260     265     270
Arg Met Asn Glu Gln Pro Arg Gln Leu Phe Trp Glu Lys Arg Leu Gln
275     280     285
Gly Leu Ser Ala Ser Asp Val Thr Glu Gln Ile Ile Lys Thr Met Glu
290     295     300
Leu Pro Lys Gly Leu Gln Gly Val Gly Pro Gly Ser Asn Asp Glu Thr
305     310     315     320
Leu Leu Ser Ala Val Ala Ser Ala Leu His Thr Ser Ser Ala Pro Ile
325     330     335
Thr Gly Gln Val Ser Ala Ala Val Glu Lys Asn Pro Ala Val Trp Leu
340     345     350
Asn Thr Ser Gln Pro Leu Cys Lys Ala Phe Ile Val Thr Asp Glu Asp
355     360     365

```

005000-444960

Ile Arg Lys Gln Glu Glu Arg Val Gln Gln Val Arg Lys Lys Leu Glu  
 370 375 380  
 Glu Ala Leu Met Ala Asp Ile Leu Ser Arg Ala Ala Asp Thr Glu Glu  
 385 390 395 400  
 Met Asp Ile Glu Met Asp Ser Gly Asp Glu Ala  
 405 410

<210> 3  
 <211> 1589  
 <212> DNA  
 <213> Unknown

<400> 3  
 cacgcgcggg cgggtgggcg gagcggcccc cctagcgggg gctgtgaagc gcggggaggg 60  
 ggccgagcgg gtggcgaagc cggcgcgcg cgggctgggg gcggagggcg gaggcccgtg 120  
 ggacagaaca gctgcggcga gtggcgcgcg cggagggagc cgaatcggcg acgagcccgg 180  
 gggtcgcaac ttgcagaagc ggcgcgcgcg gcggcatcgg ccacggcggg cggaaaagcc 240  
 ggggcgcaat ggagcggaag aggtgggagt gcccggcgct cccgcagggc tgggaaaggg 300  
 aagaagtgcc caggaggtcg gggctgtcgg ccggccacag ggatgtcttt tactatagcc 360  
 ccagcgggaa gaagttccgc agcaagccac aactggcacg ttacctgggc ggatccatgg 420  
 acctcagcac cttcgacttc cgcaccggaa agatgttgat gaacaagatg aataagagtc 480  
 gccagcgtgt gcgctatgat tcttccaacc aggtcaaggc caagcctgac ctgaacaccg 540  
 cgctgcctgt acggcagact gcatccatct tcaagcaacc ggtgaccaag atcaccaacc 600  
 accccagcaa caaggtcaag agcgaccgcg agaaggcagt ggaccagccg aggcagcttt 660  
 tctgggagaa gaagctaagt ggattgagt cctttgacat tgcagaagaa ctggtcagga 720  
 ccatggactt gcccaagggc ctgcagggag tgggccttgg ctgtacagat gagacgctgc 780  
 tgtcagccat tgcgagtgt ctacacacca gcaccctgcc cattacaggc cagctctctg 840  
 cagccgtgga gaagaaccct ggtgtgtggc tgaacactgc acagccactg tgcaaagcct 900  
 tcatggtgac agatgacgac atcaggaagc aggaggagct ggtacagcag gtacggaagc 960  
 gcctggagga ggcaactgat gccgacatgc tagctcatgt ggaggagctt gcccagagacg 1020  
 gggaggcacc actggacaag gcctgtgcag aggaggaaga ggaggaggaa gaggaggagg 1080  
 aagagccgga gccagagcga gtgtagcaca ggtgccctgc ccaagtctgg gctgcagact 1140  
 gccttcagcc ttgcctggac caggtagggg ccagacctgt aggaggcagc cgtccacctc 1200  
 ctttccaaag cctcctgctt ccaggtctca gtgcagggag cccctgtgga ccttgaactc 1260  
 acttgtccct gcgctgcctg gcaggaagcc ccacactgaa agcagatgag cagtgaccga 1320  
 actgagaggc cacctggaca cagtcacctc cctgcctcct tatcatagga caaggccttg 1380  
 cttggcaccg aggagctggg agcctgtgtg ggtgctggag gaagtttctg gaaacacacc 1440  
 tggctatgcc caccttatgt ccctaaggct attacaggcc agggtttgga ctgctccggc 1500  
 ccacagggct gccagcctc ccacactga gggtcagcag cccaccagga agtcactttc 1560  
 cttcaataaa ctgatgtag gaacttgtg 1589

<210> 4  
 <211> 291  
 <212> PRT  
 <213> Unknown

<400> 4  
 Met Glu Arg Lys Arg Trp Glu Cys Pro Ala Leu Pro Gln Gly Trp Glu  
 1 5 10 15  
 Arg Glu Glu Val Pro Arg Arg Ser Gly Leu Ser Ala Gly His Arg Asp  
 20 25 30  
 Val Phe Tyr Tyr Ser Pro Ser Gly Lys Lys Phe Arg Ser Lys Pro Gln  
 35 40 45  
 Leu Ala Arg Tyr Leu Gly Gly Ser Met Asp Leu Ser Thr Phe Asp Phe  
 50 55 60  
 Arg Thr Gly Lys Met Leu Met Ser Lys Met Asn Lys Ser Arg Gln Arg  
 65 70 75 80



Val Arg Tyr Asp Ser Ser Asn Gln Val Lys Gly Lys Pro Asp Leu Asn  
 85 90 95  
 Thr Ala Leu Pro Val Arg Gln Thr Ala Ser Ile Phe Lys Gln Pro Val  
 100 105 110  
 Thr Lys Ile Thr Asn His Pro Ser Asn Lys Val Lys Ser Asp Pro Gln  
 115 120 125  
 Lys Ala Val Asp Gln Pro Arg Gln Leu Phe Trp Glu Lys Lys Leu Ser  
 130 135 140  
 Gly Leu Asn Ala Phe Asp Ile Ala Glu Glu Leu Val Lys Thr Met Asp  
 145 150 155 160  
 Leu Pro Lys Gly Leu Gln Gly Val Gly Pro Gly Cys Thr Asp Glu Thr  
 165 170 175  
 Leu Leu Ser Ala Ile Ala Ser Ala Leu His Thr Ser Thr Met Pro Ile  
 180 185 190  
 Thr Gly Gln Leu Ser Ala Ala Val Glu Lys Asn Pro Gly Val Trp Leu  
 195 200 205  
 Asn Thr Thr Gln Pro Leu Cys Lys Ala Phe Met Val Thr Asp Glu Asp  
 210 215 220  
 Ile Arg Lys Gln Glu Glu Leu Val Gln Gln Val Arg Lys Arg Leu Glu  
 225 230 235 240  
 Glu Ala Leu Met Ala Asp Met Leu Ala His Val Glu Glu Leu Ala Arg  
 245 250 255  
 Asp Gly Glu Ala Pro Leu Asp Lys Ala Cys Ala Glu Asp Asp Asp Glu  
 260 265 270  
 Glu Asp Glu Glu Glu Glu Glu Glu Glu Pro Asp Pro Asp Pro Glu Met  
 275 280 285  
 Glu His Val  
 290

&lt;210&gt; 5

&lt;211&gt; 1966

&lt;212&gt; DNA

&lt;213&gt; Unknown

&lt;400&gt; 5

gggggcggtg ccccgagaag gcggagacaa gatggcgcc catagcgctt ggaggaccta 60  
 agaggcggtg gccggggcca cgccccgggc aggagggcg ctctgtgcmc gcccgctcta 120  
 tgatgcttgc gcgcgtcccc cgcgcgccgc gctgcgggcg gggcgggctc ccgggattcc 180  
 aaaggctcgg ttacggaaga agcgagcgcg cggctgggga gggggctgga tgcgcgcgca 240  
 cccgggggga ggccgctgct gcccggagca ggaggagggg gagagtgcgg cgggcggcag 300  
 cggcgctggc ggcgactccg ccatagagca ggggggcccag ggcagcgcmc tcgccccgtc 360  
 cccggtgagc ggctgcmcga gggaaggcmc tcggggcggc ggccgtggcc gggggcggtg 420  
 gaagcaggcg ggccggggcg gcggcgctctg tggccgtggc cggggcgggg gccgtggccg 480  
 gggacgggga cggggccggg gccggggccg cggccgtccc ccgagtggcg gcagcggcct 540  
 tggcgggcag ggccggcggt gcggcggcgg cggcagcggt ggccggcgcg ccccccggcg 600  
 ggagccggtc cctttcccgct cggggagcmc ggggcccggg cccaggggac cccggggcac 660  
 ggagagcggg aagaggatgg attgcccgc cctccccccc ggatggaaga aggaggaagt 720  
 gatccgaaaa tctgggctaa gtgctggcaa gagcgatgtc tactacttca gtccaagtgg 780  
 taagaagtgc agaagcaagc ctgagttggc aaggtacctg ggaaatactg ttgatctcag 840  
 cagttttgac ttcagaactg gaaagatgat gcctagtaaa ttacagaaga acaaacagag 900  
 actgcgaac gatcctctca atcaaaataa gggtaaacca gacttgaata caacattgcc 960  
 aattagacaa acagcatcaa ttttcaaaca accgtaacc aaagtcacaa atcatcctag 1020  
 taataaagtg aaatcagacc cacaacgaat gaatgaacag ccacgtcagc ttttctggga 1080  
 gaagaggcta caaggactta gtgcatcaga tgtaacagaa caaattataa aaacctgga 1140  
 actacccaaa ggtcttcaag gagttggtcc aggtagcaat gatgagacc ttttatctgc 1200  
 tgttgccagt gctttgcaca caagctctgc gccaatcaca gggcaagtct ccgctgctgt 1260  
 ggaaaagaac cctgctgttt ggcttaacac atctcaacc ctctgcaaag cttttattgt 1320

```

cacagatgaa gacatcagga aacaggaaga gcgagtagag caagtagcga agaaattgga 1380
agaagcactg atggcagaca tcttgtagcg agctgctgat acagaagaga tggatattga 1440
aatggacagt ggagatgaag cctaagaata tgatcaggta actttcgacc gactttcccc 1500
aagrgaaaat tcctagaaat tgaacaaaaa tgtttccact ggcttttgcc tgtaagaaaa 1560
aaaatgtacc cgagcacata gagcttttta atagcactaa ccaatgcctt tttagatgta 1620
tttttgatgt atatatctat tattcaaaaa atcatgttta ttttgagtcc taggacttaa 1680
aattagtctt ttgtaatatc aagcaggacc ctaagatgaa gctgagcttt tgatgccagg 1740
tgcaatctac tggaaatgta gcacttacgt aaaacatttg tttccccac agttttaata 1800
agaacagatc aggaattcta aataaatttc ccagttaaag attattgtga cttcactgta 1860
tataaacata tttttatact ttattgaaag gggacacctg tacattcttc catcatcact 1920
gtaaagacaa ataatgatt atattcacia aaaaaaaaaa aaaaaa 1966

```

```

<210> 6
<211> 414
<212> PRT
<213> Unknown

```

```

<400> 6

```

```

Met Arg Ala His Pro Gly Gly Gly Arg Cys Cys Pro Glu Gln Glu Glu
1          5          10          15
Gly Glu Ser Ala Ala Gly Gly Ser Gly Ala Gly Gly Asp Ser Ala Ile
20          25          30
Glu Gln Gly Gly Gln Gly Ser Ala Leu Ala Pro Ser Pro Val Ser Gly
35          40          45
Val Arg Arg Glu Gly Ala Arg Gly Gly Gly Arg Gly Arg Gly Arg Trp
50          55          60
Lys Gln Ala Ala Arg Gly Gly Val Cys Gly Arg Gly Arg Gly Arg
65          70          75          80
Gly Arg Gly Arg Gly Arg Gly Arg Gly Arg Gly Arg Gly Arg Gly Arg
85          90          95
Pro Gln Ser Gly Gly Ser Gly Leu Gly Gly Asp Gly Gly Gly Gly Ala
100         105         110
Gly Gly Cys Gly Val Gly Ser Gly Gly Gly Val Ala Pro Arg Arg Asp
115         120         125
Pro Val Pro Phe Pro Ser Gly Ser Ser Gly Pro Gly Pro Arg Gly Pro
130         135         140
Arg Ala Thr Glu Ser Gly Lys Arg Met Asp Cys Pro Ala Leu Pro Pro
145         150         155         160
Gly Trp Lys Lys Glu Glu Val Ile Arg Lys Ser Gly Leu Ser Ala Gly
165         170         175
Lys Ser Asp Val Tyr Tyr Phe Ser Pro Ser Gly Lys Lys Phe Arg Ser
180         185         190
Lys Pro Gln Leu Ala Arg Tyr Leu Gly Asn Ala Val Asp Leu Ser Ser
195         200         205
Phe Asp Phe Arg Thr Gly Lys Met Met Pro Ser Lys Leu Gln Lys Asn
210         215         220
Lys Gln Arg Leu Arg Asn Asp Pro Leu Asn Gln Asn Lys Gly Lys Pro
225         230         235         240
Asp Leu Asn Thr Thr Leu Pro Ile Arg Gln Thr Ala Ser Ile Phe Lys
245         250         255
Gln Pro Val Thr Lys Phe Thr Asn His Pro Ser Asn Lys Val Lys Ser
260         265         270
Asp Pro Gln Arg Met Asn Glu Gln Pro Arg Gln Leu Phe Trp Glu Lys
275         280         285
Arg Leu Gln Gly Leu Ser Ala Ser Asp Val Thr Glu Gln Ile Ile Lys
290         295         300

```

009060-111550

Thr Met Glu Leu Pro Lys Gly Leu Gln Gly Val Gly Pro Gly Ser Asn  
 305 310 315 320  
 Asp Glu Thr Leu Leu Ser Ala Val Ala Ser Ala Leu His Thr Ser Ser  
 325 330 335  
 Ala Pro Ile Thr Gly Gln Val Ser Ala Ala Val Glu Lys Asn Pro Ala  
 340 345 350  
 Val Trp Leu Asn Thr Ser Gln Pro Leu Cys Lys Ala Phe Ile Val Thr  
 355 360 365  
 Asp Glu Asp Ile Arg Lys Gln Glu Glu Arg Val Gln Gln Val Arg Lys  
 370 375 380  
 Lys Leu Glu Glu Ala Leu Met Ala Asp Ile Leu Ser Arg Ala Ala Asp  
 385 390 395 400  
 Thr Glu Glu Val Asp Ile Asp Met Asp Ser Gly Asp Glu Ala  
 405 410

<210> 7  
 <211> 2392  
 <212> DNA  
 <213> Unknown

<400> 7

agcggggccga ggagccgggc gcaatggagc ggaagaggtg ggagtgcgcc ggcgtcccg 60  
 agggctggga gaggaagaa gtgccagaa ggtcggggct gtcggccggc cacagggatg 120  
 tcttttacta tagcccgagc gggaagaagt tccgcagcaa gccgcagctg gcgcgctacc 180  
 tgggcggctc catggacctg agcaccttcg acttcgcac gggcaagatg ctgatgagca 240  
 agatgaacaa gagccgccag cgcgtgcgct acgactcctc caaccagggtc aagggcaagc 300  
 ccgacctgaa cacggcgctg cccgtgcgcc agacggcgct catcttcaag cagccggtga 360  
 ccaagattac caaccacccc agcaacaagg tcaagagcga cccgcagaag gcggtggacc 420  
 agccgcgcca gctcttctgg gagaagaagc tgagcggcct gaacgccttc gacattgctg 480  
 aggagctggt caagaccatg gacctcccca agggcctgca ggggggtggga cctggctgca 540  
 cggatgagac gctgctgtcg gccatcgcca gcgcctgca cactagcacc atgccatca 600  
 cgggacagct ctccggcgcc gtggagaaga acccggcgt atggctcaac accacgcagc 660  
 ccctgtgcaa agccttcatg gtgaccgacg aggacatcag gaagcaggaa gagctggtgc 720  
 agcaggtgcg gaagcggctg gaggaggcgc tgatggccga catgctggcg cacgtggagg 780  
 agctggcccg tgacggggag gcgcgcgtgg acaaggcctg cgctgaggac gacgacgagg 840  
 aagacgagga ggaggaggag gaggagcccc acccgaccg ggagatggag cagctctagg 900  
 gcagaggccc tgccgagagc ccgtgctgcc tgctggagcc gcctgcagac gcggtcctcg 960  
 gccccacgtg aaccaggctc ggccggcgaag cccagccttg gagacacca ggaggaaggc 1020  
 cgtgctcctg gtcctcctc cggcccgctc ccacttccc gggcctcggg gcacacagct 1080  
 ggggctgccc ccaccgaaa gacctccac gctcgtcctc tacagagtcc ggcttcggga 1140  
 agtgccgggt gtcctgggc cctgcctggc tccctacgac ctttgggctc gaggccagct 1200  
 cctccccatg cccgctgtcc cagctccttg agactggaga gcagccagca ggtgcccgcc 1260  
 agctcggcgc cacggcttgc tgacagctgg gagggtttct cgggtctggag gcgtagtctt 1320  
 gaaactcaca tcaccactg tgacagctga ggacgggact ctggctctgt gtggggggca 1380  
 tgcaggacgg cgccactctc tgccctgcca tgccgctggt ggtgccacag agcctcaccg 1440  
 tgccctgagt gcgtgccag ggaggcgcgt ctccttcagt aaatgtaaca cagtcgaggc 1500  
 acgtcatcgg gcagccttcc ctgtgtgcca acgccagcct tcgcttctga aaaccaaact 1560  
 ccagccgctg ccagtcggga cttggtcgcc cggcgctgcc agaattgctc actgccagcc 1620  
 ggccccctg cctcggtttc ccttctgttt agtgccgaca caggcaccga gctttgggg 1680  
 ggtgctgacg ctcccagggg tgccaggagc cactgggaca ggggtgaggct cccagacgct 1740  
 cctcgagggtg cccagctctc caggggagct ctggcccaag gcgttcttga gggatctgct 1800  
 ccttaacccc ccagtgcctt ggccagggga ggttccaagc cacagacgcc tgccccgagt 1860  
 ggacttttgc gccagtcctt ggggtccttc ctgggcctg cttgccagc gagggctcct 1920  
 aacgggtggg ttcawtggcc tggcccvagc gagccccac ctgcattgac cttaggccca 1980  
 tagagagggc ctgtcccggt gctgccccag ccaaggatct ggtcgtgcc ccagggggac 2040  
 tgatgggcaa gactgcctcc tgtggctgga ctgtgacct ccctgatggg gcctgaccgc 2100  
 gggagctgag gaagcgccgc tccacogtct gccctccaag gaccgcgatg gaggcagtgg 2160

```
<210> 8
<211> 285
<212> PRT
<213> Unknown
```


<210>	9
<211>	17
<212>	DNA
<213>	Unknown

17



# United States Patent & Trademark Office

Office of Initial Patent Examination -- Scanning Division



Application deficiencies were found during scanning:

☒ Page(s) 10 of 3 of Declaration were not present  
for scanning. (Document title)

☐ Page(s) \_\_\_\_\_ of \_\_\_\_\_ were not present  
for scanning. (Document title)

☐ Scanned copy is best available.